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OVERVIEW 
This thesis explores aspects of dementia diagnosis by investigating the quality of 
instruments used in detecting anxiety in the dementia population and the clinical 
utility of a spatial memory test in early diagnosis of dementia. 
Part 1 consists of a systematic literature review of the instruments which purport to 
measure self-reported anxiety in individuals with dementia. A total of ten studies 
reported on the methodological quality of nine instruments. The Rating Anxiety in 
Dementia (RAID) scale demonstrated the strongest weight of evidence in terms of 
the quality of measurement properties. This review highlighted a lack of high quality, 
high powered studies in this area and demonstrated the need to increase involvement 
of individuals with dementia in the validation of anxiety instruments. 
Part 2 is an empirical paper examining the clinical utility of The Four Mountains 
Test (4MT) in the early diagnosis and differentiation of Alzheimer’s (AD). In a 
secondary analysis of data, 15 structural MRI scans were analysed and compared 
with 4MT performance and other neuropsychological measures that are typically 
assessed as part of a diagnostic assessment for dementia. Contrary to prediction, 
there were no positive associations between the volume and thickness measurements 
of Regions of Interest (ROI’s) and 4MT scores across the sample. Clinical and 
research implications and limitations are discussed. 
Part 3 is a critical appraisal which reflects on the technical and methodological 
challenges of undertaking an analysis of MRI scans. It also reflects on the gaps 
between research and clinical practice in addition to conceptual and ethical 
considerations when working with individuals living with dementia. 
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ABSTRACT 
Aims: There is a high prevalence of anxiety disorders among individuals with 
dementia which affect quality of life, degree of care burden, and dementia 
progression. Screening for anxiety is important for long-term management and 
treatment. The objectives of the current review were to 1) Establish the quality of 
instruments that purport to measure self-reported anxiety in individuals with 
dementia, considering the methodological quality of studies that report on 
measurement properties. 2)Establish whether self-report or informant instruments 
provide the most reliable measurements. Methods: A range of databases were 
searched and articles were selected if their primary purpose was the development or 
assessment of measurement properties of a self-reported anxiety scale with a 
dementia sample. Methodological quality was assessed using the COnsesnus based 
Standard for the selection of health status Measurement INstruments checklist 
(COSMIN). Results: A total of ten papers reviewed nine instruments. The Rating 
Anxiety in Dementia scale (RAID) had the strongest weight of evidence for use in 
dementia. This was followed by evidence for The Brief Anxiety and Depression 
Scale (BADS). Self-report anxiety instruments demonstrated a degree of validity in 
mild-moderate dementia. However, few of these instruments have sufficient content 
validity or reliability and some lacked adequate factor analyses to determine 
structural validity. Conclusions: There have been improvements in the 
methodological quality of research in this field since a review by Seignourel, Kunik, 
Snow, Wilson, & Stanley (2008). However, further validation studies of existing 
instruments are needed to improve utility, detection, and treatment of anxiety in 
dementia. 
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INTRODUCTION 
It is estimated that approximately 46.8 million people are living with dementia 
worldwide and this figure is expected to rise to 131.5 million in 2050, if age related 
prevalence remains as it is (World Alzheimer’s Report, 2016). In the UK, it is 
estimated that there are 850,000 people living with dementia at a total cost of 
£26billion per year. This figure incorporates NHS, social care funding, and the costs 
covered by individuals with dementia and their families’ and is expected to rise to 
£55 billion by 2040 (Prince et al., 2014). There is a large body of research examining 
the neuropsychiatric and behavioural problems associated with dementia, with a 
focus on observable behaviours such as agitation, wandering, and aggression (Lai, 
2014, Reisberg et al., 2014). 
Anxiety is a common feature of dementia with considerable variability in 
estimated prevalence rates. These have varied for different types of dementia, e.g. 
38% in Alzheimer’s disease (AD) and 72% in vascular dementia (Ballard et al., 
2000). The prevalence rates for individuals with an anxiety disorder ranges from 5-
21%, while anxiety-related symptoms range from 8-71% (Seignourel, Kunik, Snow, 
Wilson & Stanley, 2008). Prevalence rates also differ depending on place of 
residence (community-dwelling vs. care homes). Twenty-five to sixty percent of 
participants across outpatient samples are reported to experience anxiety or anxiety-
related symptoms, which include, nervousness, fears, irritability, agitation, muscle 
tension, day/night disturbance, and motor restlessness (Hwang, Masterman, Ortiz, 
Fairbanks, & Cummings, 2004; Starkstein, Jorge, Petracca, & Robinson, 2007; 
Steinberg et al., 2008). Irrespective of specific focus, individuals with dementia are 
more likely to have anxiety than healthy older adults (McClive-Reed & Gellis, 
2011). Anxiety in dementia is associated with worse quality of life (QoL), reduced 
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function in activities of daily living, increased risk of nursing home placement, and 
higher caregiver burden than dementia alone (Gibbons et al., 2002; Schultz, Hoth, & 
Buckwalter, 2004; Mc Clive-Reed et al., 2011).  
The variability in prevalence rates reflects a wider lack of consensus in 
defining what is meant by anxiety in dementia. One of the reasons for this is the 
overlap of symptoms common to both mild-moderate anxiety and dementia, e.g. 
cognitive, physical, and functional deficits (Neville & Teri, 2011). Research into 
late-life anxiety and cognitive impairment is largely focused on the diagnosis of 
Generalised Anxiety Disorder (GAD; Beaudreau & O’Hara, 2008). The DSM–IV 
diagnostic criteria highlight excessive anxiety or worry as the primary symptom of 
GAD, which must be present for 6 months or longer, in addition to related somatic 
symptoms, e.g. irritability, concentration problems, restlessness, sleep difﬁculty, 
muscle tension, and fatigue (DSM-IV; American Psychiatric Association, 2000). 
Such symptoms can also be present in dementia and whether or how to determine if 
these are due to anxiety or dementia is a key issue for the assessment of anxiety. In a 
number of studies of people living with dementia (PLWD), standardised diagnostic 
tools are used while ignoring the aetiology of the anxiety (e.g., Diefenbach, Bragdon, 
& Blank, 2014; Mansbach, Mace, & Clark, 2014). This approach avoids speculation 
about the cause of the symptoms but increases the risk of inflating prevalence rates 
of anxiety disorders because of overlap with dementia symptoms. Alternatively, 
Starkstein et al. (2007) have outlined revised criteria for GAD diagnoses specific to 
AD which miss out potentially co-morbid symptoms. Fears, irritability, restlessness, 
muscle tension, and respiratory symptoms were significantly associated with 
excessive anxiety and worry, while difficulty concentrating, and sleep disturbance/ 
fatigue were not (Starkstein et al., 2007). This approach introduces rigor to the 
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process, however these adapted criteria do not appear to be widely used in the 
literature and require further validation studies (Seignourel et al., 2008). 
A further issue is the difficulty in differentiating anxiety from depression 
which frequently co-occur in individuals with Mild Cognitive Impairment (MCI) and 
dementia (Beaudreau & O’Hara, 2008; Sinoff & Werner, 2003). Significant overlap 
between these constructs has been demonstrated in MCI and dementia groups (e.g., 
Gibbons et al., 2002; Diefenbach et al., 2014). This may be a measurement issue but 
may also potentially point to the possibility that anxiety and depression do not 
represent distinct clinical entities in dementia. There are mixed results as to this from 
studies that have conducted factor analyses and it is not possible to draw overall 
conclusions due to various confounding factors across studies (Seignourel et al., 
2008), e.g. different types of dementia and use of different instruments. The 
differentiation of anxiety and depression symptoms are important for researchers and 
clinicians when developing and evaluating targeted treatments. This has implications 
for how anxiety is measured in dementia and whether instruments used in dementia 
are sensitive and specific enough to differentiate these constructs.  
There is a question as to whether self-reported anxiety by PLWD or 
carer/clinician-ratings are more reliable. Recent evidence suggests that PLWD are 
able to participate in surveys and provide consistent and accurate responses to 
quantitative questions (e.g. Snow et al, 2005; Clark, Tucke, & Whitlatch, 2008). In 
addition, an increasing number of people are being diagnosed with dementia at an 
earlier stage of disease progression (Department of Health, 2013) and are 
subsequently more likely to be able to reliably report on their own mood states. 
People with amnesia have demonstrated the ability to provide valid data about their 
current emotions, long after the source of the emotion is forgotten (Feinstein, Duff, 
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& Tranel, 2010). In addition, limbic structures involved in processing emotions are 
relatively preserved in individuals with Alzheimer’s Disease (Barnes et al., 2006). 
However, difficulties with memory and language are likely to have an effect on the 
accuracy of self-report. Anxiety in people with AD may be more reactive to the 
current environment when compared with controls (Kolanowski, Hoffman, & Hofer, 
2007). This has implications for the reliability of reporting of anxiety symptoms 
which may be overly influenced by the current context or environment. The ability of 
PLWD to report their anxiety symptoms will also be dependent on their dementia 
severity. These problems with self-report have been navigated by using caregiver-
rated measures in dementia, e.g. the Rating Anxiety in Dementia Scale (RAID: 
Shankar et al. 1999), however anxiety symptoms have been shown to be rated at a 
higher frequency in caregiver reports than in those with dementia themselves.(Burke 
et al., 1998). This has been attributed to lack of reliability of carers’ ratings, 
particularly when it comes to reporting on the cognitive symptoms of anxiety, e.g. 
excessive worry or PLWD’s subjective feelings and experiences (Dawson et al., 
2012), where carer’s reports may be invalid. 
Due to these conceptual issues, it cannot be assumed that anxiety measures 
standardised with adults or older adults can be used with the dementia population and 
the validity and reliability of anxiety measures need to be examined in a dementia 
population. Various self-report measures of anxiety and depression have been 
developed or adapted for use with PLWD. Heidenblut & Zank (2014) suggest a 
number of adaptations to instruments for use with PLWD: short and simple 
questions; fixed response sets; suitable for verbal administration and easy to 
understand and respond to. Reliable measurement of anxiety in dementia is essential 
to identifying this issue and intervening to limit its impact on health outcomes for 
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PLWD. There are no existing reviews of self-report anxiety instruments in dementia 
that use a level of evidence approach where studies are systematically ranked based 
on the rigor of their methods (Park, Reilly-Spong & Gross, 2013).  
 The primary aim is to review the quality of the instruments, considering the 
methodological quality of the studies. This will be achieved by using the Consensus-
based Standards for the selection of health Measurement Instruments (COSMIN) 
guidelines (Mokkink et al., 2010). The review will address the following questions: 
1) What is the quality of instruments that purport to measure self-reported 
anxiety in individuals with dementia, considering the methodological quality of 
studies that report on measurement properties  
2) Do self-report or informant instruments provide the most reliable measurement 
of anxiety in dementia? 
 
METHOD 
Search strategy 
The electronic databases Ovid Medline® (1946 through December 2016), 
PsycINFO® (1806 through December 2016 s), and CINAHL® (1979 through 
December 2016) were searched using the subject words dementia combined with 
anxiety. This was the search strategy adopted by a previous review of anxiety in 
dementia by Seignourel et al. (2008). A hand search of the references of the included 
papers and relevant reviews was carried out in addition to the electronic search. The 
search was limited to studies of human beings and articles published in English. 
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Selection criteria 
Articles were selected if their primary purpose was to develop or evaluate the 
measurement properties of an anxiety instrument. The instrument had to quantify 
self-reported anxiety in PLWD. and could be either a self-report measure or a 
measure incorporating self and informant reports. Studies that included mixed 
samples, i.e. those with and without a confirmed dementia diagnosis were excluded. 
Measures which included and defined separate subscales for anxiety and depression 
were included. If an article was not full-text or original (e.g. dissertations, reviews, or 
commentaries), it was excluded. Articles were also excluded if the primary aim was 
to test the efficacy of an intervention for the treatment of anxiety in dementia. The 
rationale for excluding efficacy studies was outlined by De Vet, Terwee, Mokkink & 
Knol (2011), who concluded that these studies normally provide indirect evidence of 
the measurement properties of an instrument. 2014). Quality of Life measures in 
dementia were also excluded, in addition to measures of caregiver anxiety or rating 
scales used to assess the effectiveness of interventions for carers. 
One reviewer (M.S.) carried out the screening of titles and abstracts retrieved 
in the search and selected the included articles. Two reviewers (M.S. and J.S.) 
assessed the full text of articles for inclusion and jointly made decisions regarding 
the final included articles. The steps involved in identifying and selecting the studies 
are illustrated in Figure 1. Results from the three databases were combined and 
duplicates removed, identifying a total of 1323 papers. The titles of all papers were 
screened and some were excluded based on the relevance of the titles. The abstracts 
of all the remaining papers were read to identify potentially eligible studies. The 
main reasons for exclusion at this stage included measures of caregiver anxiety, if 
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there was no dementia sample, if the instrument in the study was not a measure of 
anxiety, or if the study was a treatment efficacy study. Following this, seventy-two 
papers were retrieved, read in full, and compared against the inclusion and exclusion 
criteria. Grounds for exclusion at this stage included: absence of original 
psychometric properties; instruments which did not assess the construct of anxiety or 
worry; or there was no dementia sample. A total of twelve papers met the inclusion 
criteria and formed the set of papers for the current review.  
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Figure 1: Flow chart of search and selection process 
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Measurement properties 
The COSMIN taxonomy distinguishes three domains to assess measurement quality: 
reliability, validity, and responsiveness (Mokkink et al., 2010). Reliability is defined 
as the degree to which the instrument is free from measurement error and contains 
three subcategories: internal consistency (the degree of interrelatedness among the 
items), measurement error (the error of a patient’s score that is not attributed to true 
changes in the construct to be measured), and reliability (the proportion of the total 
variance in the measurement which is because of ‘‘true’’ differences among 
patients). Validity is the degree to which the instrument measures the construct(s) it 
claims to measure and is broken down into content, construct, and criterion validity. 
Content validity is the degree to which the content of the instrument is an adequate 
reflection of the content being measured. It includes face validity; items of the 
instrument are in line with the construct being measured. Construct validity includes 
structural validity, hypothesis testing, and cross-cultural validity. Structural validity 
refers to the degree to which scores on the instrument measure the dimensionality of 
the construct. Hypothesis testing refers to the instrument’s relationship with other 
measures that claim to measure the same construct and differ significantly from 
instruments that claim to measure different constructs. Criterion validity refers to the 
extent to which the instrument correlates with an accepted ‘gold standard’. There is 
currently no accepted ‘gold standard’ instrument to measure anxiety in dementia (see 
Siegnoruel et al., 2008), therefore an evaluation of criterion validity will not be 
conducted. 
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The COSMIN checklist and assessment of measurement quality 
One reviewer (M.S) extracted data from the selected articles and evaluated the 
measurement quality using the 4-point scale COSMIN checklist as a guide (Terwee 
et al., 2012). Each measurement property was rated as either: excellent, good, fair, or 
poor. The “worst score counts” algorithm was used in rating measurement properties. 
For example, if one element of a measurement property was defined as poor, the 
overall measurement property was considered poor. Where articles presented 
measurement properties for more than one instrument, these were presented, 
evaluated and rated as separate studies (see Table 4). 
Best evidence synthesis 
COSMIN also assesses whether studies provide positive, negative or indeterminate 
results for each measurement property based on study quality. Criteria for these 
ratings are outlined by Terwee et al. (2007) (see Table 1). Table 2 presents the 
criteria used when combining the results from the assessment of measurement 
properties and the quality of the studies reviewed
22 
 
Table 1: Quality criteria for assessment of measurement properties 
adapted from Terwee et al. (2007) and Park et al. (2013) 
Property Rating Quality Criteria 
Internal consistency   
 + Subscale unidimensional and Cronbach/s alpha(s) ≥0.70 
 ? Dimensionality not known or Cronbach’s alpha not determined 
 - (Sub)scale not unidimensional OR Cronbach’s alpha(s) <0.70 
Reliability   
 + ICC/weighted Kappa ≥ 0.70 or Pearson’s r ≥ 0.80 
 ? Neither ICC/weighted Kappa, nor Pearson’s r ≥ 0.80 
 - ICC/weighted Kappa <0.70 OR Pearson’s r< 0.80 
Content Validity   
 + The target population considers all items in the questionnaire to 
be relevant and considers the questionnaire to be complete 
 ? No target population involvement 
 - The target population considers items on the questionnaire to be 
incomplete/no information found on target population 
Structural   
 + Factors should explain at least 50% of the variance or good or 
adequate fit (see goodness-of-fit criteria for CFA or EFAa 
 
 ? Explained variance not mentioned OR equivocal fit by 
goodness-of-fit criteria for CFA or EFAa 
 - Factors explain <50% of the variance OR poor fit by goodness-
of-fit criteria for a CFA or EFAa 
Hypothesis Testing   
 + Correlation with an instrument measuring the same construct 
r=≥0.50 
 ? Solely correlations determined with unrelated constructs  
 - Correlation with an instrument measuring the same construct 
r=<0.50  
a Good or adequate fit: comparative fit index (CFI) ≥0.90, root mean square of approximation 
(RMSEA) ≤0.08, standardized root means square residual (SRMR) <0.10. Inadequate fit: CFI ≤0.85, 
RMSEA ≥0.10, SRMR ≥0.10; Indeterminate fit: the values of the fit indexes ranged in between the 
adequate criteria and inadequate criteria.
23 
 
 
Table 2: Levels of evidence for the overall quality of the measurement 
properties 
Level    Rating Criteria 
Strong  +++ or --- Consistent findings in multiple studies of 
good methodological quality OR in one 
study of excellent methodological 
quality. 
Moderate ++ or -- Consistent findings in multiple studies of 
fair methodological quality OR in one 
study of good methodological quality. 
Limited + or - One study of fair methodological quality. 
Conflicting ± Conflicting findings from studies of 
comparable quality 
Indeterminate ? Findings from excellent, good or fair 
studies were not definitively positive or 
negative 
None na Findings from excellent, good or fair 
studies were not available 
Table from Park et al. (2013) was used. This was originally adapted from Van Tulder et al. (2003) 
+positive result; -negative result; ±both positive and negative findings have been reported by studies of adequate 
quality; ? findings from studies of adequate quality were not definitively positive or negative; na findings from  
studies of adequate quality were not available. 
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RESULTS 
Across ten studies, nine instruments were evaluated and a summary of the findings 
were described for each instrument. Table 3 presents the number of studies reviewed 
per anxiety instruments. Table 4 gives details and item examples of the instruments 
reviewed. Table 5 demonstrates the methodological quality for each study, rated as 
excellent, good, fair, or poor per measurement property. Table 6 shows the level of 
evidence synthesis based on the Terwee et al, 2007 criteria (see Table 2). This 
synthesis combines the positive, negative or indeterminate ratings for each 
measurement property. It also incorporates the methodological quality of the studies, 
and the consistency of their findings. 
Table 3: Number of studies reviewed per anxiety instrument 
Anxiety Measures No. of 
studies 
Rating Anxiety in Dementia Scale (RAID; Shankar, Walker, Frost, 
& Orwell, 1999) 
4 
Geriatric Anxiety Inventory (GAI; Pachana et al. 2007). 1 
The STAI-S (Form Y 1) modified by Ward, Wadsworth, & 
Peterson (1994) 
2 
The Participant Anxiety Scale modified by Gibbons, Teri, 
,Logsdon, & McCurry, 2006 
1 
The Penn State Worry Questionnaire Abbreviated (PSWQ-A; 
Hopko et al. 2003) 
1 
 
The Worry Scale (La Barge, 1993). 1 
The Brief Anxiety and Depression Rating Scale (BADS; 
Mansbach et al., 2015) 
1 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983) 
1 
The Empirical Behavioral Pathology in Alzheimer's Disease (E-
BEHAVE-AD) Rating Scale (Auer, Monteiro & Reisberg, 1996) 
1 
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Table 4: Characteristics and item examples from the included instruments 
Instrument Construct assessed Recall period Dimensions 
(number of 
items) 
Number 
of 
subscales 
Response options 
(range) 
Ease of scoring and 
administration (range 
of scores) 
Sample items 
RAID Anxiety in dementia 
 
 
 
 
Two weeks Worry (10) 
Apprehension and 
vigilance (3) 
Motor tension (2) 
Autonomic 
hyperactivity (2) 
Phobias and panic 
attacks (1) 
Total (18) 
4 Four point-scale 
(0= absent to 
3=severe) 
Moderate: final score 
determined by clinician 
based on interview 
with the participant and 
collateral report. (0-18) 
“Worry about 
physical health” 
(Worry) 
“Sensitivity to noise, 
exaggerated startle 
response” 
(Apprehension and 
vigilance 
“Trembling” (Motor 
tension) 
GAI Anxiety One week Gastrointestinal 
(6) 
Hyperarousal (5) 
Excessive worry 
(8) 
4 Two-point scale 
(agree/disagree) 
Moderate: 20 items 
 
“I get an upset 
stomach due to my 
worrying” 
(Gastrointestinal)  
 “I often feel upset” 
(Hyperarousal) 
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Difficulty-making 
decisions (1) 
Total (20) 
“I worry a lot of the 
time” (Excessive 
worry)  
 
STAI-S 
 
State anxiety Not specified 20 items 1 Two-point scale 
(Yes/No) 
Moderate: 20 items  “I am tense”  
“I am worried”  
 “I feel calm” 
PAS Anxiety None-current 
symptoms 
12 items, 
dimensions not 
reported 
Not 
reported 
Two-point scale: 
“yes” or “no” to 
presence/absence of 
symptoms 
Easy Not reported 
PSWQ-A Worry No specific 
timeframe outlined 
Worry (8) 1 Five-point scale: 
(0=“not at all 
typical of me”) to 5 
(“very typical of 
me”). 
Moderate: ability to 
answer scaling 
questions may be 
impacted by cognitive 
impairment. 
“I know I should not 
worry about things, 
but I just cannot help 
it” 
“When I am under 
pressure, I worry a 
lot” 
The Worry 
Scale 
Dementia worry Unspecified Worry (10) 1  Five-point scale: 
“always”, “often”, 
“sometimes”, 
“rarely” and 
“never” 
Moderate: response 
options require 
temporal judgement 
“I feel worthwhile 
and satisfied with 
myself” 
“The changes in my 
memory make me 
feel I’ve lost a very 
important part of 
myself” 
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BADS-
Anxiety 
Factor 
Anxiety No specific 
timeframe outlined 
Anxiety (6) 
 
1 Three-point scale: 
“no” “somewhat or 
“yes” 
Easy: clinician reads 
statements, average of 
5 minutes to administer 
for participants with 
dementia 
“Recent increase in 
worrying”  
“Worrying about 
future” 
“Overwhelmed”  
“Nervousness”  
“Controlling worry” 
HADS- 
Anxiety 
scale 
 
Anxiety One week Anxiety (7) 1 Three-point scale 
rating frequency (0-
3) 
Easy: Administered by 
research assistant 
(0-21) 
I feel tense or 
'wound up' 
Worrying thoughts 
go through my 
mind’ 
E-BEHAVE 
AD 
Anxieties and 
Phobias 
None General anxieties 
Fear of being left 
alone 
12 0=absent 
1=Mildly present 
2=Moderately 
present 
3=Severely present 
Easy: Administered by 
trained clinician 
(0-36) 
Patient is anxious 
regarding his/her 
memory 
Other anxieties, e.g., 
about health, money, 
the future, their 
children, etc.  
Stranger anxiety 
(gets anxious when 
confronted with 
examiner) 
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Rating for Anxiety in Dementia Scale 
Description of the measure 
The Rating Anxiety in Dementia Scale (RAID; Shankar et al., 1999) contains a total 
of 18 items rated on a four-point scale (see Table 4). The original study specified 
how final ratings were decided by a clinician following interviews with the 
individual with dementia and an informant. A score of 11 or more suggests clinically 
significant anxiety. Two studies in this review (Gibbons et al., 2006; Twelftree & 
Qazi, 2006) used only caregiver ratings of anxiety.  
For the RAID, study quality ratings have been reported for the following 
measurement properties: internal consistency, reliability, content validity, structural 
validity, and hypothesis testing. Internal consistency for the RAID was positive 
assessed in three studies assessed to be of poor quality (Shankar et al. 1999; Snow et 
al. 2012; Twelftree & Qazi, 2006). Cronbach’s alpha ranged from 0.75-0.83 for the 
RAID and 0.75 for the RAID-SI (Snow et al. 2012). Inter-rater reliability was rated 
as negative in a fair quality study (Shankar et al. 1999) and positive in a poor-quality 
study (Snow et al., 2012), thus overall can be considered poor. Content validity was 
rated as excellent (Shankar et al., 1999) and this original study was subsequently 
referenced by the other studies in this review. Structural validity assessment using a 
Principal Components Analysis (PCA) suggested a one factor structure (Shankar et 
al., 1999). However, sample size was small meaning that further Exploratory Factor 
Analysis (EFA) or Confirmatory Factor Analysis (CFA) studies should be carried 
out.  
29 
 
All four studies evaluated construct validity through hypothesis testing. The 
RAID showed positive moderate–high correlations with other observer-rated anxiety 
scales (Clinical Anxiety Scale; CAS, The Anxiety Status Inventory; ASI and GAI-
collateral). There were moderate-high correlations with self-report scales (STAI-S 
and PSWQ-patient rating). Three of these studies were assessed to be of fair 
methodological quality (Shankar et al., 1999; Snow et al., 2012; Twelftree &Qazi; 
2006), while Gibbons et al. (2006) was rated as good for methodological quality. The 
RAID shows weaknesses in its ability to distinguish anxiety from other related 
constructs, e.g. there was a moderate correlation with a measure of agitation; The 
Cohen Mansfield Agitation Inventory (CMAI; Cohen-Mansfield, Marx, & Rosenthal, 
1989). In addition, correlations with a measure of depression the Cornell Scale for 
Depression in Dementia (CSSD; Alexopoulos, Abrams, Young, & Shamoian, 1988a) 
were greater than those with other measures of anxiety. 
Two studies assessed predictive validity. Shankar et al. (1999) used modified DSM-
IV criteria for Generalized Anxiety Disorder (GAD), where a score of 11 or more on 
the RAID had a 90% sensitivity and 78.5% specificity rating. Snow et al. (2012) used 
the The Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) 
as a diagnostic tool for anxiety in their dementia sample. With a cut-off score of 10, 
the RAID-Structured Interview demonstrated a 90% sensitivity rating and a 67% 
specificity rating and an area under the curve (AUC) at 0.80 (SE=0.08; 95% CI= 
0.64-0.96).  
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Levels of evidence conclusions 
Table 6 shows the results of combining both quality criteria for measurement 
properties and the methodological quality of each of the studies in analysing these 
measurement properties. The RAID had strong content validity and moderate 
structural validity and hypotheses testing validity. The reliability of the RAID is 
limited and the poor quality of the studies means that internal consistency findings 
were given no weight in this final synthesis. 
The Geriatric Anxiety Inventory 
Description of the measure 
The Geriatric Anxiety Inventory (GAI) is a twenty-item self-report instrument 
designed to measure anxiety in older people (Pachana et al., 2007). Psychometric 
properties of the measure have been reported for patients with cognitive impairment, 
demonstrating good reliability, construct, and predictive validity in diagnosing GAD 
(Byrne, Pachana, Arnold, Chalk, & Appadurai, 2008; Boddice, Pachana, & Byrne, 
2013). 
GAI study quality ratings have been reported for the following measurement 
properties; internal consistency, content validity and hypothesis testing. The 
reliability of the GAI will be addressed in a later section (see carers vs. self-report). 
Internal consistency was rated as positive. A high Cronbach’s alpha value (α=0.92) 
was reported in a study of fair methodological quality (Bradford et al. 2013). The 
GAI was developed to assess the symptoms of GAD, (e.g. fearfulness, worry, and 
physiological symptoms). However, there has been no assessment of the relevance of 
the items for people with cognitive impairment or a diagnosis of dementia. (Bradford 
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et al, 2013; Gerolimatos et al., 2013). Bradford et al. (2013) adopted fair statistical 
methods to assess the predictive validity. The GAI performed above chance in 
predicting an anxiety disorder with an AUC of 0.62 (SE=0.08). In terms of 
hypothesis testing, there was a high correlation with a measure of depression yielding 
a positive result for hypothesis testing as the constructs of depression and anxiety are 
related (Brown, Campbell, Lehman, Grisham, & Mancill, 2001; Sinoff, Ore, 
Zlotogorsky, & Tamir, 2002). 
Levels of evidence conclusions 
Evidence for the internal consistency and hypotheses testing of the GAI with 
dementia participants is limited. Reliability of the measure is indeterminate, while 
adequate content validity analysis has not been conducted. Further studies of content 
validity are required involving both PLWD and carers to judge the relevance and 
comprehensiveness of the items for this population. 
The State-Trait Anxiety Inventory-Short form (STAI-S) 
Description of the measure 
The STAI (Form Y-1; Speilberger, 1983) was adapted by Ward et al. (1994). This is 
a 20-item scale and instead of choosing one of the 4 degrees of anxiety severity (as is 
the procedure in the original measure), participants were asked to endorse each item 
by answering “yes” or “no”. Higher scores on this measure indicate greater anxiety.  
STAI-S study quality ratings have been reported for the following 
measurement properties: internal consistency, content validity, and hypothesis 
testing. Cronbach’s alpha for the measure was positive across both studies (α=0.88; 
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Twelftree &Qazi, 2006) and (α =0.91: Ward et al., 1994) however, the 
methodological quality of both were poor as there was no factor analyses referenced. 
In terms of content validity, ratings for quality were indeterminate and the 
methodological quality was poor in both studies. Ward et al. (1994) made 
adaptations to the original STAI to account for participants with dementia, e.g. 
reducing the response options and using it as a clinician-administered scale, however 
the relevance of the items was not assessed in the target population. Hypothesis 
testing yielded positive quality ratings in studies of fair methodological quality. The 
STAI-S correlated moderately with the worry subscale of the RAID (Twelftree & 
Qazi, 2006).  
Levels of evidence conclusions 
There is moderate evidence for hypothesis testing of the STAI-S. For internal 
consistency and content validity, there is insufficient evidence to draw conclusions 
about the quality of these measurement properties. 
The Participant Anxiety Scale 
Description of the measure 
The Participant Anxiety Scale is an adapted version of the Clinical Anxiety Scale 
(CAS; Westhuis & Thyer, 1989). The items for the CAS were derived from the 
criteria for anxiety disorders in the DSM-III (3rd ed.; DSM–III; American Psychiatric 
Association, 1980). It was originally designed for use in measuring anxiety in 
clinical settings and not intended for use with a dementia population. 
The study quality of Gibbons et al. (2006) is rated for the following 
measurement properties: internal consistency, content validity, and hypothesis 
33 
 
testing. Methodological quality for assessing internal consistency and content 
validity was poor and therefore these statistics are not reported. The content validity 
of the measure was taken into consideration and adaptations made to improve ease of 
use for dementia patients, e.g. adapting the response options to “yes” or “no”. 
However, there were no details provided as to which items were removed nor are 
there reported statistical methods for how these decisions were made by the authors. 
Hypothesis testing yielded negative results and the quality of this study was good. 
Correlations between the PAS and various measures of anxiety were weak (RAID 
and NPI-Anxiety Scale). There were several possible explanations for this, including; 
different symptoms measured by each of the scales, different time periods assessed, 
e.g. past two weeks with the RAID vs. current symptoms with the PAS, and variable 
rating of symptoms, e.g. the PAS is scored based on presence or absence of an 
anxiety symptom vs. the RAID score based on severity of the symptom. 
Levels of evidence conclusions 
For the internal consistency and content validity, findings from studies of adequate 
quality were not available. One study of good methodological quality; Gibbons et al. 
(2006) demonstrated a negative result for hypothesis testing. 
The Penn State Worry Questionnaire-Abbreviated 
Description of the measure 
The PSWQ-A is an abbreviated and simplified version of the PSWQ (Meyer, Miller, 
Metzger & Borkovec, 1990). It was validated with 160 older adults with GAD 
diagnoses and CFA found that a single factor model with an 8-item scale fit the data 
most optimally (Hopko et al., 2003).  
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Bradford et al. (2013) reported data on the following measurement properties: 
internal consistency, reliability, content validity, predictive validity. The 
methodological quality of Bradford et al. (2013) was rated as fair for each 
measurement property, except for the methods used to assess content validity which 
were rated as poor. Internal consistency was rated as positive (α=0.84) for PSWQ-A-
Participant and 0.89 for PSWQ-A-Collaterals. There was a negative result for 
reliability. Intra-class correlations (ICCs) considering participants and collateral 
ratings fell below the quality criteria (ICC of 0.417) with collaterals’ ratings 
exceeding participants’ ratings by an average of 5.5 points. Methods used to assess 
the content validity of this measure were poor. In terms of predictive validity, the 
PSWQ-A-Participant had an AUC of 0.691 (SE = 0.08) using the Mini-International 
Neuropsychiatric Inventory (MINI: Sheehan et al., 1998) as a comparison 
instrument.  
Levels of evidence conclusions 
There is limited evidence for the internal consistency and reliability of the PSWQ-A 
in a dementia sample. Evidence for content validity was indeterminate, while 
structural validity and hypothesis testing were not assessed. 
The Worry Scale 
The Worry Scale (LaBarge, 1993) is a 10 item self-report instrument designed for 
use with individuals with mild dementia. The items are a series of statements about 
feelings experienced in the context of memory loss, (see Table 4), therefore this scale 
specifically assesses worry related to dementia symptoms rather than anxiety 
symptoms. Study quality ratings have been reported for the following measurement 
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properties: internal consistency, reliability, content validity, and hypothesis testing. 
Internal consistency of the measure (using 8 items) was positive (α=0.85) in a study 
of fair methodological quality. In terms of reliability analysis, split-half methods 
were used demonstrating Pearson’s r values for the ‘no- dementia’ group (0.82), 
‘very mild’ (0.77) and ‘mild’ (0.80). As per the Terwee et al. (2007) criteria (see 
Table 1), the ‘no-dementia’ group and the ‘mild dementia’ group met criteria for a 
positive rating (r≥0.80). Content validity was indeterminate and the methods used 
were poor. Items were generated by professionals with experience in working in an 
Alzheimer’s research centre but there was no target population involvement. 
Structural validity was demonstrated using a PCA which indicated a unidimensional 
scale for the ‘very mild’ and ‘mild’ groups collectively. Two items were removed 
due to poor factor weightings (‘I am able to express my feelings now’ and ‘I talk to 
someone who understands what is happening to me’). Factor weightings for the 
remaining 8 items ranged from 0.45 to 0.78 in a study of fair methodological quality. 
Hypothesis testing was rated as negative using good methods. There were moderate 
correlations with both the State and Trait Anxiety measures (r= 0.55 for both). As 
expected, there was also a moderate correlation with a measure of depression (r= 
0.66) and weak correlations with state anger (r=0.32) and trait anger (r=0.31). 
However, we would not expect the correlation with depression to exceed the 
correlation with another measure of anxiety, suggesting The Worry Scale does not 
discriminate between these two constructs.  
Levels of evidence conclusions 
There is limited evidence of positive results for the internal consistency and 
reliability of The Worry Scale. There is no available evidence to draw conclusions on 
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the content validity of this measure. Finally, there is moderate evidence to suggest 
negative results for hypothesis testing, i.e. the ability of The Worry Scale to 
discriminate between anxiety and depression. 
The Brief Anxiety and Depression Scale (BADS) 
Description of the measure 
The BADS is an 8-item scale assessing symptoms of anxiety and depression based 
on Major Depressive Disorder (MDD) and GAD. Additional items were added 
including behavioural and somatic symptoms (e.g. physical complaints and signs of 
agitation) as these are often reported by depressed older adults (Mansbach et al., 
2015). 
The quality of measurement properties was reported for the following: 
internal consistency, content validity, structural validity and hypothesis testing by 
Mansbach et al. (2015). Internal consistency was rated as positive (α=0.75), however 
the quality of the methods used were poor as alpha values were not calculated for the 
anxiety and depression subscales separately. In terms of content validity, both the 
measurement property and study methods were rated as excellent. Mansbach et al. 
(2015) outlined the process of item selection, whereby various health care 
professionals reviewed the items at each stage of its development. The final 8 items 
were pilot tested in clinical settings and revised to improve clarity. Structural validity 
was rated as positive in a study of excellent methodological quality. Exploratory PCA 
demonstrated two separate components for anxiety and depression. Percentages of 
variance accounted for were 36.72% and 13.49% respectively. Only statistics 
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relevant to the assessment of the anxiety component of this measure will be reported. 
For the Anxiety Factor, a cut-score of > 4 (scores 4 and below indicating no GAD) 
yielded the optimal balance of sensitivity (73%) and speciﬁcity of (81%) for 
identifying GAD. A ROC curve was calculated and the AUC was 0.85 (SE=; 
95%CI=0.80-0.90). These results suggest that the BADS Anxiety scale can detect 
clinical anxiety in the presence of dementia. 
In terms of hypothesis testing, the study indicated positive results, however 
the quality of the methods used were deemed to be fair. The BADS anxiety factor is 
supported by a strong correlation with the Generalized Anxiety Disorder 7-item scale 
(GAD-7) (Spitzer, Kroenke, Williams, & Lowe, 2006).  
Levels of evidence conclusions 
There is strong evidence for the content validity of the measure and moderate 
evidence for its structural validity. Hypothesis testing shows limited positive 
evidence in the current study. 
The Hospital Anxiety and Depression Scale (HADS) 
Description of the measure 
The Hospital Anxiety and Depression Scale (HADS) (Zignond and Snaith, 1983) is a 
fourteen-item self-report measure of anxiety and depression. Each item is rated from 
0 to 3 and higher scores indicate greater severity of anxiety or depression.  
The aim of the Stott et al. (2016) study was to establish the structural validity of the 
HADS in a dementia sample and this was the only element of validity reported on. 
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Structural validity was rated as indeterminate in a study of excellent methodological 
quality. The percentage of missing data was outlined and listwise deletion of cases 
was employed before conducting the CFA. Three different pre-determined models 
were tested; the two-factor model suggesting anxiety and depression as separate 
constructs (Zigmond and Snaith ,1983), the one factor model suggesting one overall 
distress factor (Razavi, Delvaux, Farvacques, & Robaye, 1990), and the three-factor 
non-hierarchical model which defines ‘anxiety’, ‘depression’ and ‘negative affect’ 
(Dunbar, Ford, Hunt & Der, 2000). Both the two factors and three factors models 
met criteria for good or adequate fit as described by Terwee et al. (2007). The 
analysis did not adequately distinguish between the two-factor and three-factor 
models which makes the interpretation of the HADS in dementia uncertain. 
Additional specification searching demonstrated that the fourth item on the anxiety 
scale “I can sit at ease and feel relaxed” did not relate to the underlying construct of 
anxiety. Stott et al. (2016) suggested that removal of this item should be considered 
for people with dementia and future research into developing adjusted cut-off scores 
is required. 
Levels of evidence conclusions 
This factor analytic study provides indeterminate evidence for the structural validity 
of the HADS in individuals with mild-moderate dementia.  
The E-BEHAVE-AD 
The E-BEHAVE-AD is a 12-item clinician-rated instrument developed to assess 
behavioural pathology in Alzheimer disease and related dementia. Clinician-ratings 
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are based on a 20-minute clinical interview with the PLWD without a care-giver 
present. The symptomatic model for this scale comes from the caregiver-rated 
Behaviour Pathology in Alzheimer disease questionnaire (BEHAVE-AD). It assesses 
six pathological domains: paranoid and delusional ideation; hallucinations and 
activity disturbance; aggressiveness; affective disturbance; anxieties and phobias. 
Twelve symptoms are assessed on a 4-point severity scale, where 0 represents 
absence of the symptom across the observation period and a score of 3 represents the 
symptom with severe magnitude (Reisberg et al., 2014). 
For the E-BEHAVE-AD study quality ratings have been reported for reliability and 
hypothesis testing. 
Reliability was rated as positive in a study of poor methodological quality. A rater 
independently interviewed each participant while a second rater observed. Raters did 
not communicate and independently rated the interview. The interviewing rater was 
altered randomly. For ‘general anxieties’ the intra class correlation for raters-fixed 
was 0.86 and 0.84 for raters-random. For ‘fear of being left alone’ the intra class 
correlations were 1.00 for both raters-fixed and raters-random. (Auer et al., 1996). 
The study quality is poor for the assessment of reliability due to the small sample 
size (N=20).  Hypothesis testing was rated as negative in a study of fair 
methodological study. There was a significant correlation between the E-BEHAVE-
AD and the carer-rated BEHAVE-AD for the ‘anxieties and phobias’ category was 
statistically significant but below the r=0.50 threshold (see Table 1). 
Carers report vs self-report 
The results from the reviewed studies presented a mixed picture and did not give a 
definitive answer as to whether self-report or carer-report measures are better in 
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measuring anxiety in dementia. The RAID scoring was informed by both caregivers 
and clinician ratings and it is not clear the degree to which the self-report of PLWD 
accounted for the final clinician ratings. It is likely as dementia severity increases; 
self-report becomes less reliable (Shankar et al., 1999). When the RAID was used as 
an informant only measure, 40% of the sample were rated as scoring above the 
clinical cut-off score of 11 for anxiety (Twelftree & Qazi, 2006). This result calls 
into question the reliability of carer-only ratings as typical prevalence rates for 
anxiety among individuals with dementia ranges from 5 to 21% (Seignourel et al., 
2008). 
Collateral ratings on the GAI yielded a higher area under the curve AUC (0.81, 
SE=0.08) than participant ratings (0.69, SE=0.08). This indicates that both are only 
modestly accurate in predicting a clinical diagnosis of anxiety (Bradford et al., 2013). 
The optimal cut-off score maximising sensitivity and specificity was 8 for 
participants and 10 for collaterals. It was demonstrated that other factors such as the 
type of relationship between the participant and collateral (e.g. spouse, adult child) or 
living arrangement did not account for the degree of discrepancy between the ratings, 
however if the collateral’s gender was female, ratings were less concordant. These 
findings warrant further research into the characteristics of collaterals that may 
influence their anxiety ratings.  
PSWQ-A collateral ratings yielded a higher area under the curve AUC (0.77, 
SE=0.08) than participant ratings (0.69, SE=0.08), however this difference was not 
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significant (Bradford et al., 2013). Similar to the GAI, optimal cut-off scores were 
lower for participants (17) than for collaterals (22). 
The correlation between anxiety symptoms as rated by the E-BEHAVE AD 
and the carer-rated BEHAVE-AD was negative in a study of fair methodological 
quality. 
Overall, there is a mixed picture of results across the different anxiety 
measures as to the reliability of carer vs. self-report measures. The evidence suggests 
that both self and informant reports of anxiety symptoms are warranted in the 
assessment of anxiety in dementia. 
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Table 5 Methodological quality of each study per measurement property and instrument 
Measure Internal 
consistency 
Reliability Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Population (demographics, setting, 
diagnoses) 
RAID       
Shankar et al. 
1999 
Poor Fair Excellent Good Fair 
 
N=83, M age=79.1.  %F=62 
UK Inpatient/day hospitals. Dementia (DSM 
IV). 
Twelftree & Qazi 
2006 
Poor  Excellent  Fair N=40, M age=79.4 years. %F=70 
UK day hospitals/community. Mild-moderate 
cognitive impairment (MMSE) 
Gibbons et al. 
2006 
  Excellent  Good N=95, M age=79.9. % F=66 
US community sample. Dementia (confirmed 
by medic), anxiety (caregiver report of 3+ 
anxious or depressed behaviours). 
Snow et al. 2012 Poor Poor Excellent  Fair N=32. M age=78.6. %F=59 
US Primary care/community day hospital 
Mild-moderate dementia (confirmed by medic), 
anxiety (MINI) 
GAI       
Bradford et al. 
2013 
Fair Fair Poor   N=41. M age=79.1. %F=23 
US community sample 
Mild-moderate dementia (notes review), CDR 
score= 0.5-2. Anxiety disorders in 63.4% of the 
sample (MINI) 
Measure Internal 
consistency 
Reliability Content 
validity 
Structural 
validity 
Hypothesis 
testing 
Population (demographics, setting, 
diagnoses) 
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STAI-S       
Ward et al. 1994 Poor  Poor  Fair N=40. M age=68.8. %F: 0. US veterans’ 
medical centre. Dementia diagnosis (DSM -III)  
 
Twelftree & Qazi 
2006 
Poor  Poor  Fair See RAID 
PAS (Gibbons et 
al. 2006) 
Poor  Poor  Good See RAID 
PSWQ-A 
Bradford et al. 
2013 
Fair Fair Poor   See GAI 
 
 
 
The Worry Scale 
(La Barge, 1993) 
Fair Fair  Poor Fair Good N=182 M age=74.8. %F=64 
Very mild dementia (CDR=0.5), mild dementia 
(CDR=1) 
BADS 
(Mansbach et al. 
2015)  
Poor  Excellent Good Fair N=224 M age=80.5 %F=62 
US residential care sample. Mixed sample: 
Mild, moderate, severe Dementia (54%), no 
dementia, incl. MCI (46%) (CDR). 
HADS (Stott et 
al. 2016) 
   Excellent  N=268. M age=69.1 %F=52 
UK community sample. Mild-moderate 
dementia (DSM-IV). 
E-BEHAVE-AD 
(Auer et al., 
1996) 
 Poor   Fair N=44. M age= %F=44.9 
For reliability analysis N=20 
US community sample 
MCI (12%), AD (61%) VaD (14%), Other 
(13%). DSM III 
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N=number of participants, M age= mean age of participants, % F= percentage of females, DSM III, IV=Diagnostic and Statistical Manual of Mental Disorders, MMSE=Mini Mental 
State Exam, MINI= Mini International Neuropsychiatric Interview, CDR= Clinical Dementia Rating CIND: Cognitive Impairment, Not Dementia. MCI=Mild Cognitive Impairment. 
VaD= Vascular Dementia. AD= Alzheimer’s Disease 
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Table 6: Levels of evidence synthesis: Quality of measurement properties per instrument 
Instrument Internal consistency Reliability Content Validity Structural Validity Hypothesis testing 
RAID na - +++ ++ ++ 
PAS na na na na -- 
STAI-S na na na na ++ 
GAI + ? na na + 
PSWQ-A + - na na na 
The Worry Scale + + na + -- 
HADS na na na +++ na 
BADS na na +++ ++ + 
E-BEHAVE-AD na + na na - 
See Table 2 for levels of evidence descriptors 
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DISCUSSION 
The first aim of this study was to systematically review the quality of instruments 
which claim to measure self-reported anxiety in dementia, considering the 
methodological quality of studies. The second aim was to establish whether 
informant or self-report measures are more reliable. The COSMIN checklist was 
used to evaluate the measurement properties and the methodological quality of nine 
instruments. Internal consistency, reliability, content validity, structural validity, and 
hypothesis testing were assessed across the included studies. 
Summary of findings 
The RAID was the most frequently evaluated instrument and had the highest level of 
evidence in terms of quality of measurement properties (content validity, structural 
validity, and hypothesis testing) and methodological quality. The BADS showed 
initial strong evidence for content validity as trials involving individuals with 
dementia formed part of the item selection process. This newly developed instrument 
also demonstrated moderate evidence for structural validity. The HADS showed 
some initial evidence for structural validity but requires further research to establish 
an evidence base for a range of measurement properties when using it with a 
dementia population. The remaining instruments provided limited evidence in terms 
of the quality of measurement properties and the methodological qualities of the 
studies. 
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Limitations 
The methodological quality of many of studies in this review has been compromised 
by the problem of small sample sizes. This has implications for the degree of 
statistical power in these studies and whether this is sufficient to detect true effects, 
inflating the risk of a Type II error. Small sample size also affects the stability of 
obtained factor structures, e.g. despite a sample size of less than 100, the original 
PCA for the RAID (Shankar et al. 1999) was the basis for all further validation 
studies. Finally, this highlights the problem of representativeness and reduces the 
precision and level of confidence in extrapolating these results to the dementia 
population as a whole.  
Content validity analysis was lacking across many of the studies reviewed 
here. The inclusion of individuals with dementia in the process of item testing and 
selection is an issue which needs to be addressed. This is particularly important given 
that prior research suggests that individuals with dementia have the capability to 
participate in research using standardised measures to explore their illness experience 
(e.g. Dawson et al., 2012, Snow et al. 2005, Clark et al., 2008). In addition, selection 
of which measure to use must also consider ease of administration, completion time, 
and the needs of the target population. Some studies have made attempts at adapting 
their measures for individuals with dementia, e.g. For the GAI, participants were 
asked to report on the occurrence of experiences during the past week. It is possible 
that memory difficulties associated with cognitive impairment have an impact on the 
accuracy of self-reported symptoms of anxiety when the recall period is longer. A 
number of studies have demonstrated that individuals with memory impairments 
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have the ability to provide valid data about their current emotions (Feinstein et al., 
2010; Ready, O Carvalho, Green, Gavett, & Stern, 2011; Dawson et al., 2012).  
An important problem which this review highlights is the lack of consensus 
about what constitutes the symptoms of anxiety in dementia and the absence of a 
‘gold-standard’ instrument for diagnosing anxiety in dementia. The instruments 
reviewed here all measure slightly different things. The RAID and BADS, for 
example, measure anxiety symptoms based on DSM-IV criteria for GAD but the 
RAID includes additional items associated with somatic and behavioural symptoms 
(e.g. sleep disturbance, and motor tension). The Worry Scale assesses a range of 
emotional responses to dementia and coping styles (La Barge, 1993). Informant 
measures such as the RAID tend to use behavioural items, while self-report measures 
include more cognitive and affective aspects of anxiety (e.g., BADS; Mansbach et 
al.). Measures such as the E-BEHAVE-AD look at anxiety symptoms alongside other 
behavioural and psychological symptoms associated with dementia. Before further 
validation studies are carried out on the measures reviewed here, research in this field 
should focus on arriving at a consensus as to which specific symptoms constitute the 
concept of anxiety in dementia. This could be achieved by conducting studies which 
use Confirmatory Factor Analysis (CFA) with larger samples of individuals with 
dementia. Siegnourel et al. (2008) highlighted the problem of how research in this 
field tends to focus on initial validation of a measure followed by use of the 
instrument in research and clinical practice without further validation. However, this 
problem seems to persist, with the emergence of studies validating new measures, 
e.g. BADS (Mansbach et al., 2015). 
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Conceptual and methodological issues 
The results summarized in the current review suggested considerable overlap 
between symptoms of anxiety and depression in dementia. These results correspond 
with rates of co-morbidity in adult clinical samples, e.g. in a large clinical sample 
(N=1127), 57% of individuals with a diagnosis of a MDE also met criteria for GAD 
(Brown et al., 2001). The Worry Scale, RAID, GAI and STAI-S all demonstrated 
moderate to strong correlations with instruments that measure depression. There is 
also evidence of overlap with other related constructs, e.g. The Worry Scale was 
associated with both state and trait anger and the RAID showed an association with a 
measure of agitation.  
For studies where both participant and informant ratings of anxiety are 
considered, the RAID, GAI, and PSWQ-A indicated discrepancies. Typically, 
informants tended to rate anxiety at higher levels. It is difficult to establish the 
reasons for these discrepancies as there do not appear to be studies where priori 
hypotheses are outlined and sufficiently tested. A number of different factors have 
been proposed to influence careers ‘higher ratings, e.g. a focus on cognitive and 
functional status of the patient (Snow et al., 2005), caregiver mood (Pearson, Teri, 
Wagner, Truax, & Logsdon, 1993) and caregiver burden (Teri & Traux, 1994). 
Patient self-reported mood has been linked to deficit awareness which can impact on 
reliability (Snow et al. 2005). One exception is where care-givers are employed 
workers and not family members (Gerolimatos et al., 2015). Both caregiver burden 
and depression have been shown to negatively impact on caregiver’s ratings of 
patient’s quality of life (Karlawish, Casarett, Klocinski, & Clark, 2001; Schultz et al., 
2004). It may be that professional caregivers experience less burden than family 
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caregivers. Family caregivers have been shown to have higher levels of distress on a 
neuropsychiatric inventory, when compared with professional caregivers (Tan, 
Wong, & Allen, 2005). The authors speculated that family caregivers’ perceptions of 
their own helplessness and concerns over their abilities to control difficult behaviours 
may contribute to their higher levels of distress.  
The RAID, GAI, STAI-S and BADS all demonstrate significant negative 
correlations with various measures of cognitive impairment which indicates that 
these anxiety measures may demonstrate divergent validity. An alternative 
explanation for this result is that having more cognitive impairment is associated 
with less anxiety. Studies have shown that individuals with dementia who retain 
insight into their difficulties, experience greater levels of anxiety (e.g., Shankar et al. 
1999; Ballard, Boyle & Bowler, 1996).  
One of the strengths of the current review is the use of the COSMIN rating 
tool which introduces rigour into the process of evaluating measurement properties 
and the methodological quality of studies that report on them. A possible limitation is 
the appropriateness of the COSMIN rating tool in assessing small scale research 
studies. The psychometric properties that are impacted by sample sizes of less than 
50 participants, e.g. internal consistency, reliability and hypothesis are rated as fair 
or poor using the COSMIN criteria. Alternatively, Siegnourel and colleagues (2008) 
used four qualitative criteria for assessing the studies in their review (1) independent 
assessment of anxiety, distinguishing it as a construct separate from depression or 
agitation. (2) Instruments should contain items assessing symptoms that are less 
likely to be affected by dementia symptoms (3) instruments where possible should be 
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rated by both patients and informants and (4) instruments should have strong 
psychometric properties. 
There is sufficient evidence to indicate the use of self-report assessments of 
anxiety in individuals with mild-moderate dementia. It is difficult to conclude which 
measure is the most suitable given no instrument shows overall good or excellent 
psychometric properties. Face validity is a key factor in choosing a measure and this 
should be taken into consideration. Evidence from instruments that rate informant 
reports show that there may be important behavioural aspects of anxiety in dementia 
which can be under-reported by patients, depending on the degree of cognitive 
impairment. Where possible, informant reports should also be considered. Anxiety 
has been identified as a predictor of worse outcomes for individuals with dementia, 
therefore screening and subsequent treatment is necessary. 
Conclusion 
There is a lack of high quality, high powered factor analytic studies in this area. Stott 
et al. (2016) is the only example of a comprehensive factor analysis study with a 
sufficient sample size. Validation of existing instruments with a self-report element 
for individuals with dementia should be prioritised to improve utility, detection and 
treatment as well as content validity with larger sample sizes. In conclusion, 
instruments which screen for anxiety in dementia have the potential to be an 
important means for detection and subsequent treatment of anxiety in this population. 
Instruments have relied heavily on content analysis based on studies of older adults 
and long-term care residents. Qualitative methods such as semi-structured interviews 
and focus groups are required to involve individuals with dementia and their carers’ 
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ABSTRACT 
Aims: The current study aimed to investigate the clinical utility of a spatial memory 
test (The Four Mountains Test; 4MT) in the determining dementia subtype. In a 
previous study, the 4MT did not find significant differences between Alzheimer’s 
(AD) and non-Alzheimer’s dementia. Structural MRI data was analysed to 
investigate if neurodegeneration in the hippocampus and medial temporal lobe 
structures accounted for these non-significant differences. Method: Data were 
extracted for fifteen memory clinic patients with dementia diagnoses (AD, vascular 
and mixed dementia). This included structural MRI scans, 4MT scores, and other 
neuropsychological measures. Freesurfer image analysis suite was used for 
automated analysis of the critical neuronal structures involved in AD. The 
relationships between volumetry, 4MT performance, and cognitive abilities was 
compared across diagnostic groups. Results: Contrary to prediction, there were no 
positive associations between these variables. It was not possible to conduct 
statistical analysis to compare the AD, VaD, and the mixed dementia groups due to 
the restricted size of the final sample. Conclusions The clinical utility of the 4MT in 
distinguishing AD from other dementia types in heterogeneous groups of memory 
clinic patients has not been established. It is possible that overlapping patterns of 
atrophy and other cognitive impairments associated with dementia have a 
confounding impact on 4MT performance. However, the current study has low 
power and a lack of inferential statistics and as such the findings are tentative and 
must be interpreted with caution. However, the introduction of structural MRI data 
has contributed to further understanding of a tool that may support in the early 
diagnosis of dementia. 
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INTRODUCTION 
Dementia 
It is estimated that approximately 46.8 million people are living with dementia 
worldwide and this figure is expected to rise to 131.5 million in 2050, if age related 
prevalence remains as it is (World Alzheimer’s Report, 2016). In the UK, it is 
estimated that there are 850,000 people living with dementia at a total cost of £26 
billion per year. This figure incorporates NHS, social care funding, and the cost 
burden on individuals with dementia and their families and is expected to rise to £55 
billion by 2040 (Prince et al., 2014). Dementia is a syndrome characterized by 
deterioration in cognitive abilities beyond that which is expected in normal ageing. 
The symptoms include deficits in memory, thinking, orientation, comprehension, 
calculation, learning capacity, language and judgement (WHO, 2015). A number of 
dementia subtypes are now categorized in The Diagnostic and Statistical Manual of 
Mental Disorders (5th ed.; DSM–5; American Psychiatric Association, 2013). 
Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common dementia accounting for 
approximately 55-70% of cases (McKeel, Burns, Meuser & Morris, 2007). The 
primary symptom is memory loss with mild impairments in language and praxis 
evident at the early stage of disease progression. (McKeel et al., 2007). This is 
followed by progressive neocortical damage over the course of the disease (Wood et 
al., 2016). The AD brain is characterised by the build-up of amyloid plaques made up 
of beta proteins, and neurofibrillary tangles made up of the tau proteins. The 
accumulation of these proteins causes the degeneration of neurons (Bloom, 2014). 
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While all AD diagnoses are considered probable until confirmed by autopsy 
(Agamanolis, 2014), these AD biomarkers can be detected via amyloid PET scanning 
or CSF studies. 
Vascular Dementia 
Vascular dementia (VaD) is the second most common subtype and encompasses all 
instances of dementia associated with ischemic cardiovascular disease and 
haemorrhagic and hypoxic-ischemic cerebral lesions. (Roman et al., 1993). It is 
characterised by “an acute onset, stepwise decline, focal neurological signs, gait 
impairment and urinary difficulties” (Camicioli, 2006, pp.4). Some patients with AD 
develop symptoms of VaD over the course of the disease, usually after a stroke, 
which may result in a sudden worsening of dementia (Roman et al. 1993).  
Mixed dementia 
Dementia diagnosis is further complicated by the presence of mixed dementia where 
abnormal protein deposits associated with AD coexist with blood vessel problems 
linked to VaD (Langa, Foster & Larson, 2004). The symptoms may vary dependent 
on the brain region affected and may be like those of either AD or VaD. Research 
suggests that prevalence rates vary markedly among neuro-pathological studies from 
0% to 55%, however much of the variance is related to recruitment biases, 
geographic factors and conceptual differences. True prevalence most likely 
approximates 20% to 40% of dementia cases (Zekry, Hauw & Gold, 2002). 
Mild Cognitive Impairment 
Mild cognitive impairment (MCI) is a trajectory marked by a decline in cognitive 
function beyond that associated with typical aging (Peterson, 2011). The DSM-5 
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recognizes the importance of diagnosing this level of cognitive decline, where 
individuals may benefit from adaptations and strategies to minimise the impact on 
daily living skills. MRI data suggest that hippocampal atrophy in amnestic MCI that 
falls below the 25th percentile predicts risk of progression to a dementia diagnosis 
over a two-year period (Clifford et al. 2010). 
Other dementias 
Fronto-temporal dementia (FTD) involves degeneration of the frontal lobes resulting 
in progressive changes in behaviour, personality, executive function, or language. 
There are different forms of FTD, e.g. Pick’s disease; characterized by pathology and 
early onset and behavioral variant FTD (BVFTD); characterized by progressive 
changes in personality, emotional blunting, and/or loss of empathy. Dementia with 
Lewy bodies includes a range of cognitive deficits, including visual hallucinations. 
Huntington’s disease is an inherited dementia with features of mood, cognitive and 
gait/co-ordination deficits. 
 Alzheimer’s disease and topographical disorientation 
One of the earliest clinical features of AD is topographical disorientation. Serino, 
Cipreso, Morganti, & Riva (2014) discussed the various ways this can manifest. 
There can be difficulties using primary environmental features for orientation 
(landmark agnosia), integration of object location with respect to self (egocentric 
disorientation), memory for heading direction with respect to objects in the 
environment (heading direction), and laying down new representations of the 
environment in memory (anterograde disorientation). Topographical orientation is 
dependent on encoding, storage and retrieval of spatial information.  
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Spatial Memory and the Hippocampus 
The hippocampus plays a pivotal role in spatial memory and supports encoding of 
the context in which events occur (Ritchie et al., 2017). This is achieved via the 
storage of an internal memory model of our surroundings or a ‘cognitive map’. The 
cognitive map theory of hippocampal functioning developed out of animal 
experiments whereby place-related neuronal firing was observed in the hippocampal 
cells of freely moving rats at particular locations (O’Keefe and Dostrovsky, 1971) 
and was subsequently extended to humans (O’Keefe & Nadel, 1978; Ekstrom et al., 
2003). Two different reference frames for organising spatial information have been 
defined; egocentric and allocentric (Klatzky, 1998). Egocentric representations refer 
to memory for locations by drawing on information about the location of objects in 
relation to the self (self-centered). Allocentric representations refer to memory for 
object-to-object relations or relations between environmental characteristics and are 
unrelated to the individual’s orientation or viewpoint (world-centered). There is 
evidence to suggest that the integration of ego and allo-centric processing support the 
long-term encoding of spatial context and navigation of real world environments 
(Burgess, Trinkler, King, Kennedy & Cipolotti, 2006; Vann, 2009; Land, 2014). 
There is a prevalence of allocentric deficits among patients with MCI and AD 
with evidence suggesting that hippocampal and medial temporal lobe (MTL) 
degeneration are associated with the ability to maintain long-term allocentric 
representations of surrounding environments (Serino et al. 2014). King, Burgess, 
Hartley, Vargha-Khadem & O'Keefe (2002) used a virtual reality paradigm to test 
memory for object locations where the participants viewed objects from both static 
and shifted viewpoints. It was demonstrated that hippocampal damage impaired the 
ability to successfully retrieve memory for object location in the shifted viewpoint 
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condition. Results from studies support the conclusion that the hippocampus is 
necessary for flexible allocentric memory for object locations (Maguire & Cipolotti, 
1998; Kalova et al. 2005; Burgees et al. 2006). In addition to the hippocampal role in 
allocentric processing, functional neuroimaging studies have shown that multiple 
brain regions are activated in spatial navigation, including the left hippocampus, 
posterior cingulate gyrus, precuneus, parahippocampi via retrosplenial cortex, and 
the parieto-occipital sulcus, (Burgess, Maguire, Spiers, & O'Keefe, 2001; Iaria, Chen, 
Guariglia, Ptito, & Petrides, 2007). These regions are likely involved in 
transformations between egocentric and allocentric representations, in both 
directions. 
Allocentric representations and Alzheimer’s disease  
The MTL network activated during topographical memory tasks overlap with the 
pattern of neural degeneration in the early stages of AD (Pengas et al., 2012). While 
there is involvement of both egocentric and allocentric representations in spatial 
memory function, there is a prevalence of allocentric impairments associated with 
early AD atrophy in the MTL region (Burgees et al., 2006; Maguire & Cipolotti, 
1998). The Four Mountains Test (4MT) is a spatial memory test developed by 
Hartley et al. (2007), designed to tap the function of the human hippocampus in 
topographical processing. Participants are presented with computer-generated 
landscapes displaying four mountains in different configurations and asked to match 
one of the four images to a sample image. The test involves a spatial task where the 
target scene is presented followed by presentation of the same scene rotated to give a 
different view alongside three foil landscapes. This assesses the ability to recognize 
places from their layout even when the viewpoint changes (see Figure 1; Chan et al., 
2016). A non-spatial task is also given, where participants match to sample based on 
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non-spatial elements e.g. cloud cover, lighting, and colour of vegetation. To assess 
both spatial perception and memory, the match-to-sample task is administered 
immediately after presentation of the target image and again after a delay. Hartley et 
al. (2007) found that participants with focal hippocampal damage had significant 
difficulty with spatial memory but showed spared abilities in spatial perception, non-
spatial perception, and non-spatial memory. 
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Figure 1: The Four Mountains Test (4MT)  
 
(A) All 4MT stimuli are based on computer-generated heightfields containing 4 mountains as 
illustrated by a sample contour map (see A). Each landscape is made up of similar topographical 
features: the ground plane with small scale undulations, a semi-circular mountain range (defining the 
horizon in each image), and 4 prominent mountains of varying shapes and sizes. An example is shown 
as a contour map in. Images are rendered using a virtual camera placed at one of the indicated 7 
locations. (B) Participants see a sample image which they study before seeing four different images 
(one target showing the same place from a different viewpoint, and 3 foils showing different places). 
Their task is to identify the target. (C) Example of a sample image. (D) Corresponding target and foil 
images (the target is seen top-left). Note that all images are shown at the same scale in the test, and 
that viewpoint and other non-spatial features are systematically varied between sample and test 
images (Chan et al., 2016, p 2) 
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Spatial memory testing and distinguishing dementia type 
Spatial memory testing has demonstrated the ability to discriminate between 
different dementia subtypes, e.g., the 4MT has been demonstrated to discriminate 
between AD and non-AD dementias (Hartley et al., 2007; Pengas et al., 2012). 
Topographical memory has been shown to be preserved in FTD (Bird et al., 2010) 
and in semantic dementia (Pengas et al., 2010). A virtual supermarket task of spatial 
orientation was able to discriminate between AD and bvFTD, independent of 
episodic memory performance (Tu et al., 2015). Impaired orientation was associated 
with the integrity of the parietal rather than temporal lobes indicating that this novel 
task tapped the egocentric framework. These results suggest that neuropsychological 
testing of spatial memory may provide diagnostic specificity and indicates a possible 
utility for routine testing of these abilities in clinical assessments. 
There is evidence to suggest that the 4MT has clinical utility in determining 
whether patients with MCI will develop AD in the future. Patients with amnestic 
MCI, thought to be in a prodromal AD stage showed similar performance on the 
4MT as those with a diagnosis of AD, indicating utility of the 4MT in detecting the 
presence of prodromal AD (Bird et al., 2010). Performance on the 4MT was 
incorporated with neuroimaging results to demonstrate that 4MT scores of <8 were 
associated with 100% sensitivity and 90% specificity for detection of MCI patients 
with AD biomarker status and those without (Moodley et al., 2015). In addition, 
4MT performance correlated with hippocampal volume and cortical thickness of the 
precuneus and posterior cingulate gyrus, which is consistent with the role of these 
regions both in spatial memory and the brain pathology of early AD. Most recently, 
the 4MT predicted conversion from MCI to AD with a 93% accuracy in a group of 
15 patients followed up over a 24-month period (Wood et al., 2016), which is 
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comparable to the predictive power of more invasive methods such as CSF studies of 
amyloid and tau. 
The utility of the 4MT task may be less clear in a real-world diagnostic 
setting. Gore (2015) examined the clinical utility of the 4MT in differentiating 
between dementia type, including AD, VaD, mixed dementia, and MCI in 
participants recruited in a memory service. Unexpectedly, there was no significant 
difference in 4MT scores between the AD group and other dementia types, a finding 
that is not in line with previous studies, (Hartley et al., 2007; Pengas et al., 2010; 
Moodley et al., 2015). In addition, other neuropsychological measures, including 
memory performance, did not demonstrate significant differences between the AD 
and the VaD groups as hypothesized. 
Current Study 
Research has identified that hippocampal atrophy in AD is associated with the ability 
to represent and remember allocentric spatial information (Maguire et al., 1998; 
Burgess, et al., 2006; Hartley et al. 2007). Initial evidence for the clinical utility of 
the 4MT in distinguishing between different types of dementia has been 
demonstrated (Hartley et al., 2007; Pengas et al., 2012), particularly in predicting 
disease progression from MCI to early AD (Bird et al. 2010; Moodley et al., 2015; 
Wood et al. 2016). However, these results have not been replicated in more 
heterogeneous groups of dementia patients, for example, when individuals with VaD 
and mixed dementia are included (Gore, 2015). An explanation for this discrepancy 
is the possible overlap in hippocampal and MTL atrophy in AD, VaD, and mixed 
dementia. In AD there is a stereotypical pattern of MTL degeneration (entorhinal and 
hippocampal) and neuroimaging can support in differential diagnosis (Frisoni, Fox, 
73 
 
Jack, Scheltens, & Thompson, 2010). Investigating the relationship between 4MT 
and MTL atrophy typical of AD has the potential to increase understanding of the 
utility of the 4MT in diagnosis and subsequent treatment of dementia. Furthermore, 
previous research suggests that other brain regions surrounding the hippocampus are 
implicated in spatial memory processes e.g. the volume of the entorhinal and 
parahippocampal regions predicted familiarity memory in older adults, MCI, and 
early AD patients (Wolk, Dunfee, Dickerson, Aizenstein, & DeKosky, 2011). 
Entorhinal volume has been shown to be associated with recognition of the spatial 
environment based on familiarity (Yonelinas et al., 2007). 
There are a number of cognitive abilities required to perform the 4MT 
including, visuo-spatial, language, memory, verbal fluency, executive functioning, 
and pre-morbid functioning abilities. Deficits in these abilities have the potential to 
confound 4MT performance. The neuropsychological measures used to assess these 
abilities are described in the method section.  
Aims 
Some studies have found an association between 4MT and volumetric changes in 
specific brain regions (Hartley et al., 2007; Pengas et al., 2012) and found that scores 
on this test are predictive of conversion from MCI to AD, but when investigated in a 
mixed dementia sample (Gore, 2015), it was not found to discriminate. The current 
study aims to explore the volumetric changes to search for an explanation for this 
inconsistency. A volumetric analysis of critical brain structures associated with 4MT 
performance was conducted. The regions of interest (ROI’s) investigated were the 
volume of the hippocampus, entorhinal cortex, and parrahippocampal gyrus. The 
rationale for exploring these regions comes from functional neuroimaging studies 
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which implicate these structures in spatial navigation tasks (Burgess, Maguire, 
Spiers, & O'Keefe, 2001; Iaria, Chen, Guariglia, Ptito, & Petrides, 2007).  The 
thickness of the precuneus and posterior cingulate gyrus were also investigated as per 
results from Moodley et al. (2015), where correlations between the volumerty of 
these regions and 4MT performance were demonstrated.  Furthermore, the current 
study replicated the methodology of Moodley et al. (2015) using a more 
heterogeneous clinical sample; firstly, by including participants with VaD and mixed 
dementia and secondly by using a sample with an older average age (78.80 years) 
compared with Moodley’s UK study average age (65.63 years).  
 
Hypotheses 
1) The 4M task was designed to specifically depend on the function of the network of 
ROIs stated in the aims above. Thus, we predict positive associations between the 
volume and thickness measurements of the ROIs and 4MT scores across the sample.  
2) It is predicted based on the Gore (2015) finding of no difference on the 4MT task 
between the different dementia subtypes, that in the current sample there will be 
similar levels of volumetric atrophy across these subtypes. Differences in the 
volumes of the critical structures in the main diagnostic categories (AD, VaD, and 
mixed dementia) will be investigated. 
3) Evidence in this field is limited to “pure” AD and MCI samples rather than mixed 
samples from diagnostic services (e.g. Hartley et al, 2007; Moodley et al. 2015). An 
investigation of associations between volume and thickness measurements and the 
neuropsychological measures available may clarify our understanding of the 
relationships between dementia subtype, volumetry, and psychometric findings. 
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METHOD 
Design 
A cross-sectional observational design was used to explore how brain volumes and 
thickness of the ROI’s related to 4MT scores and to performance on other cognitive 
measures.  
Setting 
Scans were available for participants across two NHS Memory Services and their 
associated Dementia Advisor services provided by the Age Concern Charity. These 
services were based in West London. Research appointments were carried out in 
participant’s homes or at the memory service. The cognitive measures used in the 
current study were administered as part of a study by Gore (2015). Permission to use 
the data was obtained from the primary researcher (see Appendix 1). The participants 
involved were also part of a wider dementia study about accessibility of Cognitive 
Behavioural Therapy (CBT) for older people with dementia. The measures described 
in the current study were used as a means of assessing the cognitive abilities required 
to benefit from CBT treatment. The first published study from this wider project was 
published by Stott, Scior, Mandy, & Charlesworth (2017). 
Participants 
Inclusion/Exclusion Criteria 
All participants who had been referred to memory services or were involved with the 
dementia advisor services were initially considered eligible for the study. Participants 
invited to participate had met the following criteria: 
• Fluent in English language and did not require use of an interpreter. 
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• Aged 50 years or over. 
• Scored above 70 on the Addenbrooke's Cognitive Examination- III at the 
initial assessment (ACE-III). 
• No current significant mood or anxiety disorders, psychotic symptoms, 
substance misuse problems or a premorbid learning disability. 
• No sensory difficulties that would interfere with completion of 
neuropsychological measures i.e. problems with sight. 
• Deemed to have capacity to consent to take part in the study. 
 
The sample included patients with a range of memory difficulties and 
subsequent dementia diagnoses were heterogeneous. Scores below 70 on the ACE-III 
tend to be indicative a more moderate to severe dementia. More global deficits in 
functioning can be expected regardless of dementia type. Capacity to consent in 
accordance with the Mental Capacity Act (2005) was also re-assessed at the research 
appointment. Eligibility for the current study was determined by the availability of an 
MRI brain scan. 
Diagnostic assessment 
ICD 10 criteria were used to make dementia diagnoses. A clinician from the memory 
service gathered information by conducting a clinical interview and administering the 
ACE-III as a test of cognitive abilities. In most cases an MRI scan was used as 
supplementary information in arriving at a diagnosis. In some cases, participants 
were referred for further neuropsychological testing if their presentation was more 
complex. Results from all assessments were discussed in a multidisciplinary team 
77 
 
and a diagnosis was determined. Following this, patients were informed about 
diagnosis by an assigned clinician. 
Ethics 
The work was covered by ethical approval for the original study which was granted 
after review by the City Road and Hampstead National Research Ethics Service 
Committee. An amendment to the original ethics application was submitted to 
confirm neuro-radiological data could be analysed under the original consent 
procedure and this was approved by the committee in July 2015 (see Appendix 2 for 
letter granting ethical approval). 
Sample Size 
As this study consists of a secondary data analysis, the sample had been recruited and 
tested in advance so using a power analysis to specify a sample size was not possible. 
It is now apparent that the current study is underpowered for parametric analysis due 
to the unexpected lack of availability of MRI data for some of the participants. While 
this study is underpowered for the research hypotheses, it provides preliminary data 
in a field of research with few prior studies. As a result, it was decided to proceed 
with a more descriptive approach in addition to tentative inferential analyses. The 
availability of a heterogeneous clinical sample warranted an exploratory analysis to 
help establish the likely magnitude of effects. The use of small available samples is 
well-established in neuropsychological research, and this study aimed to make the 
best possible use of difficult-to-collect data. 
Measures 
The neuropsychological measures were administered in the original study. This data 
was used to characterise the sample and examine relationships between brain region 
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volumes and thickness, 4MT, and other cognitive abilities. The researcher who 
administered the neuropsychological tests was trained and experienced in this field. 
Demographic information was also collected both during the testing and 
retrospectively using the NHS electronic patient database. The orders of the tests in 
the battery were randomized using Qualtrics, an online survey system designed for 
administering research protocols. This enabled the researchers to allow for the 
potential impact of fatigue and carry-on effects on performance. The following 
measures were used to explore the research hypotheses in the current study: 
 
The Test of Premorbid Functioning (TOPF) (Wechsler, 2011) was administered to 
assess pre-morbid intellectual ability prior to the onset of dementia. The TOPF 
consists of a list of seventy words irregular words and takes less than 10 minutes to 
complete. The TOPF demonstrates good internal consistency (Cronbach’s alpha = 
0.95). The test-retest reliability is also good (corrected correlations between r=.89 
and r=.95; Wechsler, 2011). The TOPF correlates with the Wechsler Adult 
Intelligence Scale- Fourth Edition (WAIS-IV) Full Scale IQ scores. The raw score, 
sex, years of education, and other demographic variables can be combined to 
calculate an estimated premorbid IQ score. The measure can be used to predict sub-
scale scores on the WAIS-IV and Wechsler Memory Scale (WMS). Research has 
established the TOPF as a valid method for assessing change between premorbid and 
current cognitive functioning with a clinical dementia sample (Duff, Chelune, & 
Dennett, 2011). In a recent small-scale study (N=33), the TOPF underestimated pre-
morbid IQ when compared with a demographic equation model (McDonald, 2015). 
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The Addenbrooke's Cognitive Examination-III (ACE-III; Mioshi, Dawson, 
Mitchell, Arnold, & Hodges, 2006) is the updated version of the ACE-R. It assesses 
the following cognitive functions: attention/orientation, memory, verbal fluency, 
language and visuo-spatial abilities (see Appendix 3). Minor adaptations to ACE-R 
items have been made (e.g. repetition, comprehension and visuospatial). The test is 
scored out of 100 and higher scores reflect better ability. Internal reliability of the 
ACE-III, measured by Cronbach’s alpha was 0.88 and there was a strong correlation 
with the ACE-R (Hsieh, Schubert, Hoon, Mioshi & Hodges, 2013). The ACE-III also 
shows high sensitivity and specificity with cut-off scores at 88 (sensitivity=1.0; 
specificity=0.96) and 82 (sensitivity=0.93; specificity1.0) (Velayudhan et al. 2015). 
 
Trail Making Test (TMT) (Reitan, 1992) is a measure of visual search, scanning, 
speed of processing, mental flexibility, and executive functions (Tombaugh, 2004). It 
is a pen-and-paper task containing two parts; the task of Part A is to connect a set of 
twenty-five numbers in consecutive order as fast as possible while maintaining 
accuracy. This task measures visual search and motor skill speed. In Part B, 
participants alternate between a series of numbers and letters, maintaining 
consecutive order of each set. This task measures mental flexibility (Bowie & 
Harvey, 2006). Test-retest reliability is reported at r=0.80 (Spreen & Strauss, 1991) 
and validity r= 0.59 (Delis, Kaplan, & Kramer, 2001). The TMT is susceptible to the 
effects of the normal ageing process as demonstrated by increased time taken to 
complete Parts A and B in the absence of sensory or motor deficits (Wahlin, 
Bäckman, Wahlin, & Winblad, 1996). When comparing MCI and AD patients to 
controls, errors demonstrated a greater sensitivity to diagnostic category than to the 
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presence of an impaired time to completion score (Ashendorf et al., 2008). This 
suggests that Parts A and B can be considered separately. 
 
The 4MT is a spatial memory test designed to measure hippocampal-dependent 
topographical memory processing in humans (see Hartley et al., 2007). The validity 
of the 4MT has been demonstrated by research which indicates poor performance on 
the 4MT in individuals with focal hippocampal damage, despite preserved abilities in 
spatial perception, non-spatial perception and non-spatial memory (Hartley et al. 
2007). Poor performance on the 4MT has also been shown in Alzheimer’s disease 
patients (Bird et al. 2010; Moodley et al., 2015), where hippocampal atrophy is a 
defining feature of this dementia subtype. Formal psychometric properties of the 
4MT have not yet been established as it is an experimental instrument that has only 
been used in a series of laboratory-based research studies. 
 
Participants completed the topographical memory subtest of the 4MT (see Hartley et 
al. 2007 for further details). The aim on this subtest is to retain the topographical 
layout information of a computer-generated landscape and to identify this target 
image among a selection of 4 images (3 foils and 1 target image). A non-spatial task 
is also given, where participants match-to-sample based on non-spatial elements e.g. 
cloud cover, lighting, and colour of vegetation. Participants were presented with a 
target image on a computer screen for 10 seconds and then a blank screen for 
approximately 2 seconds. On the next computer slide, 4 alternative landscape scenes 
were presented that were arranged randomly in a 2 by 2 grid. Participants had twenty 
seconds to select the correct target image. Answers were recorded independently by 
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the participant using a grid sheet. The test was administered on a laptop but the 
researcher controlled the laptop and the timings of the images. This was to reduce the 
need for participants to interact with the computer interface and to minimize potential 
confounds. 
 
Procedure 
The Freesurfer image analysis suite was used to analyse T1 structural images. This 
software is documented and freely available for download online: 
(http://surfer.nmr.mgh.harvard.edu/). Automated analysis was used to extract left and 
right volumes of the hippocampi, parrahippocami and entorhinal cortices and the 
thickness measurements of the posterior cingulate gyri and precunei. 
Cortical Reconstruction 
The first stage of this this process performed all of the cortical reconstruction. This 
involved motion correction and averaging of the T1 structural images (Reuter et al. 
2010). There may be variations in anatomical intensity induced by artefacts such as 
the radio-frequency coil, the acquisition pulse sequence, and by the nature and 
geometry of the sample itself (Belaroussi, Milles, Carme, Zhu, & Benoit-Cattin, 
2006). It also involved removal of non-brain tissue (Segonne et al., 2004), for 
instance removing the skull from the MRI images. This was followed by automated 
Talairach transformation and segmentation of the subcortical white matter and deep 
grey matter volumetric structures (including hippocampus, amygdala, caudate, 
putamen, ventricles) (Fischl et al., 2002; Fischl et al., 2004a). Talairach 
transformations refer to a map of human brain structures (known as an 'atlas'). These 
are used to map the location of brain structures independent from individual 
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differences in the size and overall shape of the brain (Lancaster et al., 2000). The 
automatic subcortical segmentation involves several stages of processing (see 
http://surfer.nmr.mgh.harvard.edu/ for further details). (1) CGA linear registration: 
aligning the initial registration to a template. (2) Canonical Normalization: a further 
normalization process. (3) Canonical Registration: computes a nonlinear transform to 
align with the atlas. (4) Neck removal: differentiating and removing the neck from 
the MRI volume. (5) Registration with skull: computes transform to align MRI 
volume with the atlas volume possessing the skull. (6) Subcortical labelling: labels 
the subcortical structures according to the atlas. Freesurfer morphometric procedures 
have been demonstrated to show good test-retest reliability across scanner 
manufacturers and across MRI field strengths (Han et al., 2006; Reuter et al., 2012). 
Out of the eighteen images processed during the cortical reconstruction stage, 
seventeen images were viable. Two scans were excluded as they did not contain 
enough DICOM (Digital Imaging and Communications in Medicine) images for 
processing. 
Brain mask 
When the cortical reconstruction process finishes, it is possible that errors may have 
occurred in distinguishing white and pial surfaces. The brain mask function displays 
the skull-stripped surfaces to allow for manual inspection of coronal, sagittal and 
horizontal slices (see figure 2 for sample image). The white surface (blue line) is 
used to calculate total white matter volume and should accurately follow the 
boundary between white matter and grey matter. The pial surface is used to calculate 
cortical grey matter volume and should accurately follow the boundary between the 
grey matter and the CSF. Images were excluded for one participant at this stage as 
the brain mask process failed. 
83 
 
Quality control checks 
A quality control check of all the MRI images was undertaken. The Enigma 
instructions for visual quality control were followed 
(http://enigma.ini.usc.edu/protocols/imaging-protocols/protocol-for-quality-control-
and-summary-statistics/). Enigma is an international consortium which has pooled 
the human brain images and genome-wide scans of 21,000 participants. The Enigma 
Consortium aims to gain a greater understanding of brain structure and function, 
based on MRI, DTI, fMRI, and genetic data. Examples of successful and poor 
labelling were obtained from the Enigma website and the study images were 
compared against these as a first step in the visual quality control process (see figure 
3 and 4). The primary researcher (M.S.) identified six images which deviated from 
the successful labelled examples due to the presence of deep sulci and severe 
atrophy. These images were reviewed by two researchers (S.C. and J.K.) and a 
consensus was reached to include these six images. Through making comparisons 
with the Enigma examples of successful and poor labelled images, it was evident that 
the software had located the anatomical boundaries in brains with significant atrophy 
and no anatomical mislabelling was identified. More importantly, no obvious 
mislabelling was evident in the regions of interest, i.e. the medial temporal lobes. 
Subcortical segmentation and parcellation 
Statistical output files were generated for each participant during the initial stage of 
processing. These were generated for the subcortical segmentation (aseg) and the 
cortical parcellation (aparc). The statistical output from the subcortical segmentation 
contained the volumes of specific structures, while the statistical output from the 
cortical parcellation contained the thickness of specific structures. Tables were 
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generated to include measures of area, volume, and thickness of the labelled regions 
for individual participants. 
 
Figure 2: A sample output brain mask image generated by Freesurfer.  
 
Figure 3: Visual quality control of FreeSurfer results: Examples of successful 
reconstructions. 
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Figure 4: Visual quality control of FreeSurfer results: examples of unsuccessful 
reconstructions.  
 
 
Data Analysis 
Data were entered and graphed with scatterplots using Microsoft Office Excel 2016 
to examine the distribution of volumes and thickness measurements across the 
dementia groups. Statistical Package for the Social Sciences (SPSS) version 24.0 was 
used to run a series of Pearson’s Correlation Coefficients to explore relationships 
between scores on the 4MT, scores on neuropsychological tests, and different 
dementia diagnoses.  
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RESULTS 
Thirty-two participants for whom there was 4MT data available met the inclusion 
criteria for the current study. Eighteen structural MRI brain scans were available for 
analysing. Two participants were excluded at this stage as their scan files did not 
contain enough images for processing. One scan failed at the brain mask stage and 
was therefore excluded from further analysis. Eleven participants had both viable 
scans, neuropsychological data, and 4MT scores available for analysis. There were a 
further 4 participants who had not been administered the 4MT as part of their 
research assessment and had available scans with corresponding neuropsychological 
data. It was decided to include these participants in the study in order to investigate 
correlations between brain atrophy and neuropsychological measures.  
Participant Characteristics 
The demographic information and baseline neuropsychological data for the sample 
(N=15) are presented in Table 1. Descriptive statistics (means and standard 
deviations) are reported in Table 2 a. The scores for Trails B were not analysed as 
participants with time completion scores exceeding 300 seconds were not recorded. 
Pearson correlation coefficients were used to investigate relationships between 4MT, 
neuropsychological measures, and volumetry data throughout.  
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Table 1: Demographic and clinical characteristics of the participants  
 N  % Mean SD 
Age (years) 15  - 78.80 6.26 
Years of Education 15  - 13.53 3.38 
ACE score 14  - 75.21 10.66 
Dementia Diagnosis      
AD 8  53.3 - - 
Vascular Dementia 3  20.0 - - 
Mixed Vascular and 
AD 
4  26.7 - - 
Gender      
Male 8  53.3 - - 
Female 7  46.7 - - 
Ethnicity      
White British 9  60.0 - - 
Irish 1  6.7 - - 
White Other 4  26.7 - - 
Black Caribbean 1  6.7 - - 
Baseline scores      
Estimated Premorbid 
Functioning 
15  - 48.47 14.45 
Memory 14  - 15.36 5.40 
4MT 11  - 9.82 3.31 
Visuo-spatial 14  - 13.07 1.64 
Mean scores with standard deviations and the range. Neuropsychological data based 
on raw scores for ACE and TOPF. 
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Table 2: Means and standard deviations of the neuropsychological measures for 
each dementia subtype 
  Dementia Diagnosis 
 AD 
N=8 
VaD 
N=3 
Mixed AD & VaD  
(N=4) 
Age (Years) 78.63 
(7.89) 
81.00 
(4.36) 
77.50 
(4.20) 
Education (Years) 13.63 
(4.31) 
14.00 
(2.65) 
13.00 
(2.16) 
 
4MT 9.67(N=6) 
(3.89) 
9.67 
(3.79) 
10.50 (N=2) 
(2.12) 
ACE-III Total 76.14(N=7) 
(10.29) 
69.67 
(9.07) 
77.75 
(13.57) 
ACE-III Memory 15.00 (N=7) 
(5.80) 
14.00 
(2.65) 
17.00 
(6.98) 
ACE-III Attention 15.57 (N=7) 
(2.73) 
15.33 
(1.53) 
14.25 
(4.27) 
ACE-III Language 22.57 (N=7) 
(2.23) 
 
21.00 
(3.46) 
21.50 
(1.00) 
ACE-III Visuo-spatial 13.57 (N=7) 
(1.40) 
 
11.00 
(1.00) 
 
13.75 
(1.26) 
ACE-III Fluency 9.43(N=7) 
(2.23) 
 
8.33 
(2.08) 
 
11.25 
(1.50) 
Trails Making A 
(seconds) 
41.14 (N=7) 
(24.50) 
 
49.47 
(10.69) 
 
45.75 
(18.30) 
 
Raw scores reported for ACE, Trails Making Test and TOPF. 
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Hypothesis 1 
The 4M task was designed to specifically depend on the function of the network of 
ROIs investigated. Thus, we predict positive associations between the volume and 
thickness measurements of the ROIs and 4MT scores across the sample.  
 
Table 3: Pearson’s Correlations between ROIs and 4MT scores across all dementia 
groups (N=11) 
 r p value 
Volumes  
Left hippocampus -.03 .94 
Right hippocampus -.07 .83 
Left entorhinal .15 .66 
Right entorhinal .27 .42 
Left parahippocampus .09 .80 
Right parahippocampus .06 .87 
Thickness   
Left posterior cingulate gyrus .10 .78 
Right posterior cingulate gyrus -.20 .95 
Left precuneus .32 .34 
Right precuneus .38 .12 
*Correlation is significant at the 0.05 level (2-tailed) 
P=participant 
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Scatterplot observations 
It was not possible to statistically analyse differences between AD, VaD, and mixed 
dementia due to the small sample size. To explore these data, a series of scatter plots 
were graphed (see Figure 5). This method was adopted by Chan et al. (2016) and 
Moodley et al. (2015) to describe observations in the dataset. A cluster of AD 
participants (N=5) showed relatively higher 4MT scores alongside right posterior 
cingulate thickness measurements on the lower end of the scale. A group of four AD 
participants cluster together with 4MT scores ranging from 9 to 11 and left precuneus 
thickness measurements ranging from 1.94mm- 2.32mm. Three AD participants 
show 4MT scores ranging from 9-11 and left entorhinal volume between 1127mm 
and 1408mm. 
 
Figure 5: Scatterplots demonstrating 4MT scores and volume and thickness 
measurements of the ROIs (N=11) 
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Hypothesis 2 
It is predicted based on the Gore (2015) finding of no difference on the 4MT 
task between the different dementia subtypes, that in the current sample there 
will be similar levels of volumetric atrophy across these subtypes. Differences in 
the volumes of the critical structures in the main diagnostic categories (AD, 
VaD, and mixed dementia) will be investigated. 
The mean volume of the left hippocampus was lower in the AD group vs. both the 
VaD, and mixed groups (see table 4 for means and standard deviations). For the right 
hippocampus, the mixed dementia group showed the lowest mean volume. The VaD 
group had the lowest mean volumes for left entorhinal, right entorhinal, left 
parahippocampus, right parahippocampus, left posterior cingulate gyrus and left 
precuneus thickness. The AD group had the lowest mean thickness measurement for 
the right posterior cingulate gyrus. For right precuneus thickness, the VaD and the 
mixed dementia groups had lower mean volumes. 
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Table 4: Means and standard deviations (SD) of scores for volume and thickness 
measurements for each dementia subtype 
  Dementia Diagnosis 
AD 
N=8 
VaD 
N=3 
Mixed AD & 
VaD  
(N=4) 
Volume (mm3) 
Left Hippocampus 
 
Mean 
SD 
2723.75 
(535.69) 
2898.07 
(225.58) 
2926.43 
(343.98) 
 
Right Hippocampus Mean 
SD  
3011.39 
(544.32) 
 
3045.20 
(293.96) 
2849.52 
(318.00) 
Left entorhinal Mean 
SD 
1427.50 
(291.07) 
1179.67 
(308.46) 
1496.75 
(454.91) 
Right entorhinal Mean 
SD 
1493.75 
(294.07) 
 
1194.67 
(270.06) 
1491.75 
(225.97) 
Left 
parahippocampus 
Mean 
SD 
1647.38 
(322.77) 
1362.00 
(300.49) 
1474.75 
(360.93) 
 
Right 
parahippocampus 
Mean 
SD 
1627.00 
(250.84) 
1302.33 
(51.79) 
1726.75 
(275.64) 
 
Thickness (mm) 
 
Left posterior 
cingulate gyrus 
Mean 
SD 
2.48 
(.24) 
 
2.40 
(.23) 
2.57 
(.22) 
Right posterior 
cingulate gyrus 
Mean 
SD 
2.33 
(.212) 
2.48 
(.123 
2.40 
(.160) 
Left precuneus Mean 
SD 
2.15 
(.19) 
 
2.03 
(.27) 
2.23 
(.21) 
Right precuneus Mean 
SD 
2.15 
(.15) 
 
2.13 
(.24) 
2.13 
(.09) 
 
 
 
    
Hypothesis 3 
Evidence in this field is limited to “pure” AD and MCI samples rather than 
mixed samples from diagnostic services (e.g. Hartley et al, 2007; Moodley et al. 
2015). An investigation of associations between volume and thickness 
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measurements and the neuropsychological measures available may clarify our 
understanding of the relationships between dementia subtype, volumetry, and 
psychometric findings. 
There were no significant correlations between ACE memory scores and volume and 
thickness measurements in the sample. In terms of diagnostic category, there was a 
small cluster of AD participants (N=3) with relatively reduced right posterior 
cingulate gyrus thickness, ranging from 2.05mm to 2.17mm coupled with a scores of 
13 for ACE memory (see figure 6). 
There was no correlation between ACE attention scores and volume of the 
left entorhinal cortex. There was a positive correlation between ACE fluency scores 
and the volume of the left (r=0.58, p=.04) and right entorhinal cortices (r=.66, 
p=.11). There was also a positive correlation between ACE fluency scores and the 
volume of the right parahippocampus (r=.59, p=.030). There were no significant 
correlations between TOPF scores and volume and thickness measurements. Looking 
to diagnostic category, there was a cluster of AD participants with reduced volumes 
of the left hippocampus and the posterior cingulate gyri who had higher estimated IQ 
scores when education, age and gender were accounted for (see figure 6). 
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Figure 6: Scatterplot demonstrating volumes and thickness measurements of the 
ROIs and ACE memory, ACE attention and TOPF scores.
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Comparisons with normative data 
There are no available normative data for the 4MT measure, therefore comparisons 
are made with the group means from studies that included a comparison group of 
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healthy participants. The overall sample mean (M=9.82), for 4MT was lower than 
that of a group of healthy controls in a UK sample (M=11.10, N=20), but marginally 
higher than an Italian sample (M=9.00, N=10) in the Moodley et al. (2015) study. A 
further study by Bird et al. (2010) demonstrated a mean 4MT score of 10.70 for a 
group of healthy controls (N=25). In the current study, the AD (M=9.67), VaD 
(M=9.67), and mixed dementia groups (M=10.50) average 4MT scores were lower 
than the means for healthy control samples (Bird et al. 2010; Moodley et al., 2015). 
The average ACE scores for the full sample and for each dementia type are compared 
with normative data in Table 5. 
Table 5: ACE scores for the full sample and as per dementia type compared 
with the normative sample. 
 ACE mean 
scores 
(N=14) 
AD  
(N=7) 
VaD M 
(N=3) 
Mixed AD 
& VaD  
(N=4) 
Normative 
data 
95% CI 
ACE-III Total 75.21 71.00 
 
71.00 
 
82.50 
 
96.0 
(95.2-96.6) 
 
ACE-III Memory 15.36 13.00  
 
13.00 
 
19.00 24.60 
(24.30-
25.00) 
ACE-III Attention 15.14 15.00  
 
15.00 16.00 17.60 
(17.5-17.8) 
ACE-III Language 21.93 23.00  
 
23.00 
 
21.00 
 
25.30 
(25.20-
25.60) 
ACE-III Visuo-
spatial 
13.07 13.00  
 
11.00 
10-12 
14.00 
12-15 
15.5 
(15.3-15.7) 
ACE-III Fluency 9.71 10.00  
 
 
9.00 
6-10 
11.00 
10-13 
12.6 
(12.3-12.9) 
M=mean scores, 95% CI= 95% confidence intervals 
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DISCUSSION 
Summary of results 
This study aimed to explore associations between 4MT performance and volumetric 
changes in a heterogeneous sample of memory clinic patients. It was predicted that 
there would be positive associations between the volume and thickness 
measurements of ROIs and 4MT scores across the sample. Contrary to prediction, 
there were no positive associations between these variables. It was not possible to 
conduct statistical analysis to compare the AD, VaD, and the mixed dementia groups 
due to the restricted size of the final sample. The data showed that higher 4MT scores 
coincided with relatively reduced right posterior cingulate gyrus thickness and 4MT 
scores between 9-11 coincided with left precuneus thickness and left entorhinal 
volume.  
It was predicted based on the Gore (2015) finding of no difference on the 
4MT task between AD, VaD and mixed dementia, that in the current sample there 
would be similar levels of volumetric atrophy across these subtypes. It was not 
possible to conduct statistical analyses to investigate differences in volumes and 
thickness measurements between the diagnostic groups due to small sample size. 
Through examination of means and standard deviations, the AD group did not show 
higher degrees of atrophy across the ROIs. The AD group had the lowest mean 
volume for the left hippocampus and right posterior cingulate gyrus thickness. The 
VaD group showed the lowest mean volume for left entorhinal, right entorhinal, left 
parahippocampus, right parahippocampus, left posterior cingulate gyrus, and left 
precuneus thickness. The mixed dementia group had the lowest mean volume for the 
right hippocampus. 
99 
 
Evidence from studies exploring the utility of spatial memory testing in 
predicting dementia subtype is limited to “pure” AD and MCI samples rather than 
mixed samples from diagnostic services (e.g. Hartley et al, 2007; Moodley et al. 
2015). An investigation of associations between volume and thickness measurements 
and the neuropsychological measures available attempted to clarify our 
understanding of the relationships between dementia subtype, volumetry, and 
psychometric findings. There were no significant correlations between ACE memory 
scores and volume and thickness measurements in the sample. The mean ACE-
memory scores were below the normative cut-offs and therefore it was expected that 
memory performance may be related to neurodegeneration in the hippocampus and 
MTL, but this was not the case in this sample. There was a positive correlation 
between ACE fluency scores and the volume of the left and right entorhinal cortices 
and the volume of the right parahippocampus. Looking to diagnostic category, there 
was a cluster of AD participants with reduced volumes of the left hippocampus and 
the posterior cingulate gyri who had higher estimated IQ scores when education, age 
and gender were accounted for. 
Comparison with previous research 
The current findings do not support the evidence from previous studies which have 
demonstrated that impairments in hippocampal-dependent allocentric memory can 
distinguish AD from non-AD dementia (Hartley et al., 2007; Pengas et al., 2012; Tu 
et al., 2015). 
Interpretation of findings 
The current study is underpowered and therefore these results must be cautiously 
interpreted. There is a risk of falsely rejecting the null hypothesis in underpowered 
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studies (Cohen, 1988, 1992), therefore it cannot be concluded that there is no 
relationship between 4MT performance and the structural measurements of the MTL 
regions. When p values >0.05, it can neither be concluded that the null hypothesis is 
false, nor can it be assumed that the null hypothesis is true (Vadillo, Konstantinidis 
& Shanks, 2016). Underpowered studies have lower probability that any observed 
effect will pass the p < 0.05 threshold (Button et al. 2013). The current sample size 
was not large enough to detect associations between the variables. A power analysis 
was conducted prior to commencement of this research project and this was based on 
a sample size of 32 participants from the Gore (2015) study. For exploring the 
possible association between 4MT and volumetry of the ROIs, the study was 
powered for a medium to large effect. However, only eleven viable MRI scans were 
available for comparison with 4MTscores. It was not possible to collect further data 
as the available sample were memory clinic patients for whom structural brain 
regions and performance on the 4MT and other neuropsychological measures were 
obtained at a pre-diagnostic phase. This underpowering is a result of unexpected 
problems with the quality of the scans obtained which was only detectable after a 
commitment had been made to the project. Due to the time restriction of doctorate 
research, it was not possible to recruit and test a new sample. There is a wider 
problem in terms of the prevalence of underpowered studies in psychological 
research and more specifically within neuroscience research. For example, by 
extracting data from meta-analyses of structural brain abnormality studies between 
2006 and 2009, Ioannidis (2011) showed that the median statistical power of 461 
studies was 8 per cent. Furthermore, the dichotomous nature of Null Hypothesis 
Significance Testing (NHST) sets an arbitrary threshold which can lead to 
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researchers concluding the null hypothesis is true if a study fails to reject the null 
(Hoekskra, Finch, Kiers & Johnson, 2000; Vadillo et al., 2016). 
Exploring relationships between brain pathology and cognitive functions 
using structural MRI assumes a modular understanding of human cognitive 
functioning.  Exploring relationships between 4MT scores and degrees of atrophy of 
specific ROI’s excludes the possible effect of disrupted functional connectivity 
between different regions, which is an established phenomenon in the literature 
(Sporns, Chial, Kaiser & Hilgetag, 2004). It is likely that a complex range of inter-
connected systems are involved in topographical disorientation (see review by 
Serino, Cipresso, Morganti, & Riva, 2014). A number of different techniques have 
been adopted to investigate functional networks of various brain regions, e.g. EEG, 
PET and resting state fMRI (Tomasi & Volkow, 2011; Delbeuck, Van Der Linden & 
Collette, 2003). These studies support the hypothesis of Alzheimer’s disease as a 
neocortical ‘disconnection syndrome’ that compromises both structural and 
functional connectivity of cortical white matter tracts (Leuchter et al., 1992, Rose et 
al. 2000). In AD patients, resting state fMRI studies have demonstrated disrupted 
connectivity between the hippocampal formation and the medial prefrontal cortex, 
ventral anterior cingulate cortex, right infrotemporal cortex, right cuneus and 
precuneus, left cuneus, right superior and middle temporal gyri and the posterior 
cingulate cortex (Wang et al., 2006). Evidence for a disconnection syndrome in AD 
extends more broadly across whole brain networks, e.g. an anterior-posterior 
disconnection between pre-frontal and parietal lobe regions using resting brain state 
analysis (Wang et al., 2007) and when engaged in cognitive tasks, such as immediate 
and delayed memory for faces (Grady et al. 2001). 
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Low statistical power means that it is not possible to draw meaningful 
conclusions from these results, however previous studies with adequate power to 
detect effects have shown no significant association between the thickness of the 
posterior cingulate gyrus and 4MT performance, e.g. Moodley et al. (2015). In the 
current study, contrary to predictions, higher 4MT scores coincided with relatively 
reduced right posterior cingulate gyrus thickness. The posterior cingulate gyrus is 
typically involved in early AD (Minoshima et al., 1997; Scheff et al., 2015) and has 
been linked to a broader region known as the brain’s ‘default mode network’ which 
facilitates free-thinking and the generation of self- relevant mental explorations, e.g. 
anticipating and mental rehearsal of possible future events (Lehmann et al., 2010). 
The role of the ‘default mode network’ in AD is evidenced by fMRI and PET studies 
(Buckner, Andrews-Hanna & Schacter, 2008). This network includes “the posterior 
cingulate cortex (PCC), precuneus, dorsal and ventral medial prefrontal, lateral 
(mainly inferior) parietal cortices, and medial temporal lobes” (Mevel. Chetelet, 
Eustace & Desanges, 2011, p.2). Episodic memory impairment, the hallmark of MCI 
and AD has been shown to be induced by disruption to functional connectivity 
between the PCC and the cingulum bundle (Chtelat et al., 2003; Villain et al., 2008). 
The links between declining cognitive functions typical in AD and functional 
connectivity between different brain regions provides a further rationale for 
investigating connections between MTL regions rather than MTL atrophy in 
isolation. 
Another possible explanation for the absence of expected effects is the 
validity of dementia diagnoses. Diagnoses of dementia cannot be confirmed until 
post-mortem analysis is undertaken as the current methods available for making a 
clinical diagnosis of dementia are only an estimation of suspected underlying 
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pathology. Rates of diagnostic accuracy vary from 52 to 100% for AD (Molsa et al., 
1985, Victoroff et al., 1995) and between 21 and 95% for VaD (Knopman et al., 
2001). In a more recent study by Gay et al. (2008), increasing age was associated 
with neuropathological diagnoses via post-mortem. Out of a sample of 221 older 
adults 67.8 % of the clinically diagnosed patients received a definitive diagnosis of 
AD, VaD or mixed dementia. The sensitivity for AD was 75.9 % and specificity was 
60.6 %.  
 
Correlations between memory deficits and atrophy were not borne out in the 
results. This finding is not in keeping with the established function of the 
hippocampal and MTL structures in episodic memory functions. One possible reason 
for this is the validity of ACE-III as a tool for detecting neural change over time in 
dementia (Larner & Mitchell, 2014). ACE fluency scores were correlated with the 
entorhinal cortices and right parrahippocampal volume. This result is in keeping with 
the established role of the temporal lobes in language abilities. A major contributing 
factor to the non-significant correlations between 4MT, volumetry, and other 
cognitive functions is likely due to a smaller sample size than expected. This means 
the study is underpowered. The implications of this are discussed in detail below (see 
limitations section).  
Limitations 
The main limitation of this study is the smaller than anticipated sample size and 
consequent lack of statistical power to detect effects. The implications of these 
limitations have been addressed in the interpretation of findings section. 
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The exclusion of a healthy control group for comparison with the dementia 
groups is a limiting factor in the research. Longitudinal designs are recommended for 
future research in this area. Furthermore, a number of cognitive factors may have had 
an influence on 4MT performance, e.g. the correlation between verbal fluency and 
entorhinal and right parahippocampal volumes may indicate that language difficulties 
associated with cognitive decline may have had a confounding influence on 4MT 
performance. The possible influence of premorbid abilities was highlighted by 
observations in the data. These results demonstrate a cluster of AD participants with 
greater pre-morbid intellectual abilities. This trend in the data highlights the possible 
need for premorbid IQ matching of participants as higher premorbid IQ may be a 
protective factor in dementia. The cognitive reserve hypothesis proposes that higher 
IQ, education, occupational attainment, or participation in leisure activities act as 
protective factors that may modulate the clinical expression of AD pathology (Stern, 
2006). 
The use of structural MRI has associated methodological weaknesses e.g. the 
Freesurfer tool automatically segments between white matter and grey matter which 
is used to map the location of brain structures independent from individual 
differences in the size and overall shape of the brain (Lancaster et al., 2000). It is 
possible that errors can occur during this process. There is a possibility that the one 
scan which failed at the skull strip stage of processing could have been investigated 
further and if appropriate, manual adjustment of the parameters could have been 
applied. This was not possible due to the sole researcher’s limited skills and training 
in this area. The complexity of volumetric analysis may also lead to variations in 
findings; for example, decisions about adjustments for intracranial volume may be 
taken earlier or later in the process leading to systematic differences. Moodley et al. 
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(2015) corrected for total intracranial volume after averaging between left and right 
hemispheres before running their correlations between 4MT and the ROI’s.  
Clinical Implications 
The findings of the current study are not sufficient to determine the reliability of the 
4MT for use in dementia diagnosis with heterogeneous groups that attend memory 
clinics. The finding that hippocampal and MTL atrophy is common to AD, VaD, and 
mixed dementia in this sample may account for the non-significant differences in 
4MT performance, however lack of statistical power does not allow for statistical 
conclusions to be drawn from the results. Previous research has demonstrated that the 
4MT is sensitive and specific in predicting conversion from MCI to AD, identifying 
individuals with biomarkers and in distinguishing AD from rarer forms of dementia 
e.g., FTD and semantic dementia. However, previous studies have suggested that 
overlap in structural degeneration between the most common types of dementia may 
mean that the 4MT is not specific enough in differential diagnosis and clinicians may 
need to rely on other clinical features of each of the dementia subtypes (see Gore for 
references) Subtyping in dementia is important in terms of treatment decisions. It is 
estimated that approximately 60% of patients with AD demonstrate subjective 
improvements with memory drug treatments, whereas these drugs are not effective in 
VaD and not indicated due to possible side effects (Department of Health, 2014).  
Difficulties with spatial memory identified by individuals with dementia and 
their carers include; difficulty or inability to remember familiar and unfamiliar 
environments, learn new routes, use maps and recognize places. The 4MT is a 
laboratory developed test based on research which pinpoints a specific deficit in 
allocentric memory in AD patients. These homogenous samples have been tested in 
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controlled environments using rigorous diagnostic assessment procedures. It is likely 
that in a heterogeneous clinical sample other cognitive deficits apart from allocentric 
representations may be at play when it comes to spatial memory deficits.  
Future research 
It would be beneficial to replicate this study with a larger sample size to address the 
issues with power previously discussed. This would also allow group differences to 
be compared statistically and provide more robust evidence about possible 
differences or similarities between the dementia subtypes. A larger sample would 
also allow for the use of logistic regression using a stepwise approach to select the 
best cognitive and neuronal predictors of dementia type (AD versus non-AD). The 
inclusion of patients with MCI would allow investigation of the utility of the 4MT at 
an earlier stage of the disease process, where previous research has demonstrated the 
4MT’s sensitivity and specificity in predicting conversion to AD.  
Future research in this field may benefit from the use of neuroimaging 
techniques that identify metabolic activity in the brain, e.g. fMRI, PET, and SPECT. 
In AD, resting-state metabolic activity in the brain’s ‘default mode network’ has 
been shown to correlate with the distribution of amyloid plaques (Buckner et al., 
2008; Mintun et al., 2006a). These neuro-imaging techniques may contribute to a 
greater understanding of how spatial representations are mapped in different 
dementias and therefore support the refinement of behavioural measures for use in 
differential diagnosis. It is important to note the challenges and ethical considerations 
when balancing the potential research benefits of using invasive imaging procedures 
with the clinical needs of participants with dementia. In addition, further studies are 
warranted using measures that can separate out and control for the influence of 
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egocentric processing, e.g. the virtual reality Starmaze navigation task (Bellassen et 
al. 2012). This would also allow for an investigation of the possible deficits in the 
translation between these two reference frames. 
Conclusions 
It was not possible to determine the clinical utility of a test of hippocampal-
dependent spatial memory, the 4MT in distinguishing AD from other dementia types 
in heterogeneous groups of memory clinic patients. This was due to lack of statistical 
power to detect possible effects that have been demonstrated in previous studies. It is 
possible that overlapping patterns of atrophy across different dementia types in 
clinical samples confound the use of this test, which claims to specifically measure 
hippocampal-dependent allocentric representations. Other cognitive impairments 
associated with dementia may also have a confounding impact on the performance of 
spatial memory tests. This is an exploratory study with low power and a lack of 
inferential statistics and as such the findings are tentative and must be interpreted 
with caution. However, the introduction of structural MRI data has contributed to 
further understanding of a tool that may support in the early diagnosis of dementia. 
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Introduction 
This critical appraisal will be a personal reflection on my experiences of undertaking 
a secondary analysis of data and a discussion of the conceptual, ethical, and personal 
issues associated with research into early diagnosis of dementia. Firstly, I will begin 
by discussing my motivations for the choice of both the systematic literature review 
and the empirical project. This will be followed by a discussion about the challenges 
of conducting a secondary analysis of data and overcoming technical challenges. I 
will reflect on the limitations of the analysis and findings and discuss implications 
for clinical practice. I will conclude this critical appraisal with discussing the broader 
conceptual issues of early diagnosis, stigma and lived experiences of dementia. 
Motivations for choice the of research topics 
The World Health Organisation (2012) highlighted dementia as a global challenge. A 
broad public health approach is recommended to improve care and enhance quality 
of life for people living with dementia and their family caregivers. The G8 summit 
outlined ambitious global plans for a cure or a disease modifying therapy for 
dementia by 2025. There are a raft of similar global initiatives and national 
campaigns with a focus on future goals. Meanwhile, there are a large number of 
individuals currently living with dementia who may benefit from early diagnosis and 
intervention to improve health outcomes and maintain or improve quality of life. I 
have observed the pivotal role that clinical psychologists play in the assessment and 
treatment of people living with dementia, for example, pre-diagnostic counselling, 
obtaining informed consent for assessment, cognitive and neuropsychological 
assessment, communicating about dementia diagnosis, and delivering post-diagnostic 
124 
 
psychosocial interventions (BPS, 2014). In addition, I have experience working with 
individuals with dementia and have carried out a broad range of neuropsychological 
assessments in my clinical work. As such, I was motivated to undertake my own 
research and contribute to the growing body of evidence aiming to improve care and 
outcomes for individuals with dementia and their caregivers. 
The choice of my systematic literature topic differed from that of the 
empirical paper as I wanted to capture a different aspect of the lived experience of 
individuals with dementia. Evidence suggests that anxiety is prevalent (Seignourel, 
Kunik, Snow, Wilson, & Stanley (2008) and CBT treatment with adaptations has 
been shown to be effective in the mild-moderate stages of dementia (NICE, 2006). It 
was important for me to choose a topic to highlight mental health difficulties in this 
population. In my clinical work as a trainee psychologist, I have witnessed the 
impact of behavioural and psychological symptoms associated with dementia, how 
these are perceived and treated and the impact on the individual and their family 
caregivers. A greater recognition that individuals with dementia suffer co-occurring 
mental health difficulties which lead to worse health outcomes was important for me 
to highlight and investigate in the systematic literature review. 
When I first started to explore options for the major research project the idea 
of taking on a secondary analysis of data was unfamiliar but appealing. From 
previous experiences of recruiting clinical and non-clinical samples for 
undergraduate and MSc research, I was struck by the time, effort, and willingness of 
the participants to contribute. This was often part of fulfilling an aim to further 
scientific knowledge or improve health outcomes for themselves and others. These 
aims are often not achieved because of a long history in psychological research of 
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prioritising publication of significant findings to the detriment of important 
replications and null findings (Laws, 2013). For this reason, a secondary analysis 
struck me as a more responsible and ethical approach; using data that had already 
been collected to answer different but related questions and further knowledge in the 
field of early diagnosis of dementia. 
Secondary analysis and technical challenges  
The decision to analyse neuroimaging data as the main task of this project presented 
a number of challenges. Getting to grips with the technicalities of Freesurfer 
processes presented a steep learning curve for me. I had initially anticipated that I 
could learn these skills with support from my research supervisor and collaborator 
and apply them independently to analyse the data. In reality, this process was more 
complex and required a collaborative approach with my research supervisor and the 
external collaborator working together to figure out the process and troubleshoot 
problems. Due to my lack of experience and previous knowledge, there were times 
where I felt out of my depth with this process. It helped to discuss these challenges 
with my research supervisor who helped me to appreciate which elements of the 
process were more important to understand, for example, understanding the 
technicalities of Freesurfer code was unnecessary and my efforts were better placed 
in understanding the segmentation and mapping processes so that I could make 
informed decisions about the analysis. 
I also questioned the reliability and accuracy of the Freesurfer automated 
analysis. While automated methods provide more time-efficient analysis of data 
compared with manual investigations, they still require operator input and vigilance 
with regards to quality control checks (Bigler, 2015). It was beneficial to spend time 
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with my supervisor and external collaborator discussing observations of the 
processed scans in order to carry out quality control checks. Furthermore, caution 
must be exercised when interpreting automated segmentation in older people with 
dementia as both age-related atrophy and vascular disease have an impact on the 
delineation of white, grey and CSF boundaries, which can sometimes be less well 
defined and irregular in the older adult population (Wenger et al.;2014; Clerx et al. 
2015).  
In the initial stages of the research project, the technicality of the language 
used to describe the Freesurfer processes and the medical terminology in the research 
literature were difficult to understand and I noticed that I was at risk of not being able 
to critique the methods until I had a greater understanding of how they operated. 
Learning about these concepts was essential to interpreting the results and 
generalising the findings. The generalizability of findings in this research field is 
compromised by inconsistencies between research studies, e.g. automated analysis 
may differ as a result of using different operating systems (Gronenschild et al.,2012) 
and the degree of smoothing and image modulation used (Scarpazza et al., 2015). 
Conducting this research has highlighted the importance of understanding the 
methods used in research studies in order to critically appraise the findings. In the 
past I have found myself skimming over complex method sections, particularly in 
neuropsychology research papers that use imaging techniques. This research has 
highlighted the need to examine research methods more carefully and critically. 
Learning these new skills has given me insight into working with the methods 
and techniques of neuroimaging and the need to collaborate with disciplines outside 
of clinical psychology to pursue neuroimaging research. I have acquired skills and 
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knowledge in neuro-imaging techniques and functional neuroanatomy. As a trainee 
clinical psychologist, I feel better prepared to liaise and consult with multi-
disciplinary colleagues in working with dementia and other neurological conditions.  
Limitations 
Deriving a sample size was the main difficulty encountered during this process and 
subsequent issues with power was the main limitation of the study. Undertaking a 
secondary analysis of previously collected data meant that further recruitment was 
not possible. The first stage of cortical reconstruction was not possible for three of 
the participants due to the lack of images available for processing. At the brain mask 
stage, it was not possible to manually inspect the skull stripped images for one 
participant as Freesurfer identified an error. A solution to Freesurfer segmentation 
problems is to manually define the parameters between subcortical white matter and 
deep grey matter structures (Perlman, 2007), however this task was beyond my skills 
in this area and so it was decided to exclude this participant from further analysis. 
The lack of available scans to match the neuropsychological dataset meant that there 
were no scans available for MCI participants and this dementia subgroup were not 
represented in this study. Finally, four participants for whom MRI scans had been 
processed and analysed did not have available 4MT scores, as the measure was not 
completed as part of the diagnostic assessment. These participants were included for 
comparison with other neuropsychological measures. These developments with 
availability of data were disappointing as they impacted on the sample size and 
power to detect possible significant relationships between the variables. Historically, 
a criticism of neuropsychological research is the use of small sample sizes, hence 
studies that are statistically underpowered for the hypothesis being investigated 
(Millis, 2003). These setbacks highlighted the challenges of conducting research in 
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clinical settings and the problems with retrospectively obtaining data for secondary 
analysis. 
Exploring relationships between brain pathology and cognitive functions 
using structural MRI assumes a degree of functional specialization and a modular 
understanding of human cognitive functioning. The suggestion that a test like the 
4MT correlates with the structural make-up of a specific brain region runs the risk of 
being reductionist as anatomical and functional connectivity are well established 
phenomena in the literature (Sporns, Chial, Kaiser & Hilgetag, 2004). It is likely that 
a complex range of inter-connected systems are involved in topographical 
disorientation (see review by Serino, Cipresso, Morganti, & Riva, 2014). 
Recruitment of a larger sample size would have allowed for the selection of data-
driven regions of interest across diverse neuronal networks followed by statistical 
modelling where different structural measurements are incorporated into a single 
statistical model that relates to performance on the 4MT. This approach was adopted 
by Cook et al. (2014) for investigating the diverse neural correlates of verbal fluency 
in FTD. 
Implications for clinical practice  
Carrying out this project has highlighted the gap between experimental research and 
clinical practice in dementia care. There is a strong focus in the literature of 
identifying dementia at the preclinical and early stages of the disease and this in stark 
contrast with the diagnostic rates in the UK where only 46% of individuals with 
dementia will receive a formal diagnosis at any stage (Department of Health, 2013). 
The utility of spatial memory testing in differentiating dementia subtypes e.g. FTD 
and AD, or predicting conversion from MCI to AD has been shown to be possible in 
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homogenous research samples, however these studies do not account for the high 
prevalence of vascular disease in the dementia population. Clinical studies in western 
memory clinics show varying prevalence rates from 4.5 to 39 % and these figures are 
likely to be an underestimation as diagnostic criteria only show moderate sensitivity 
(approximately 50%) and variable specificity (64-98%) (Mc Aleese et al., 2016). For 
cognitive tests to have utility in memory clinics, tools that aid in diagnosis need to be 
tested on more heterogeneous groups of individuals with dementia and inclusion of 
VaD. 
The time gap between presentation at primary care services and disclosure of 
diagnoses in a memory clinic setting represents a possible ‘window of opportunity’ 
for investigating progression from MCI to AD by conducting neuropsychological 
testing and MRI imaging at this stage. However, this methodological design raises 
ethical considerations. It is possible that there may be a risk of undue psychological 
distress associated with participation in a study investigating diagnosis of dementia 
without the individual and family receiving a confirmed diagnosis and access to 
support around this. 
Early diagnosis of dementia  
The process of investigating the utility of the 4MT in early diagnosis of dementia has 
encouraged me to reflect on the pros and cons of early diagnosis. There is a general 
consensus among health care professionals regarding the benefits of early diagnosis, 
e.g., reducing uncertainty, planning support and avoiding crises, and organising 
future support plans and legal arrangements (Iliffe, Manthorpe, & Eden, 2003). Early 
detection improves access to treatments which are indicated in the earlier stages of 
the disease process. NICE (2006) recommend that people with mild-to-moderate 
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dementia of all types should be given the opportunity to participate in a structured 
group cognitive stimulation programme (CST). CST has demonstrated evidence of 
significant improvements in measures of cognitive function and improved quality of 
life (Spector et al., 2003). In a qualitative study exploring the psychological impact 
of early diagnosis, over half of participants highlighted benefits including; 
appreciation and acceptance of life; less concerns about failure; self-reflection, 
tolerance of others, and courage to face problems in life; strengthened relationships 
and new opportunities to meet people (Moore et al., 2016).  
There are ethical considerations with early diagnosis of dementia and 
concerns over accuracy of diagnostic tools, particularly in the MCI stage. Even when 
tests have diagnostic accuracy of approximately 90% (e.g. CSF studies), this still 
results in a large number of misdiagnosed persons, considering that the prevalence 
rate of AD in MCI cohorts is 50% (Mattson, Brax & Zetterberg, 2010). There is an 
increased risk of suicide in dementia, which may be linked to co-morbid mood 
disorders or as a result of associated stigma (Draper, Peisah, Snowdon, & Brodaty, 
2010). The stigmatizing reactions of others, e.g., the individual with dementia being 
accused, restricted, ignored or patronized by others (Steeman, De Casterle, Godderis, 
& Grypdonck, 2006) is another important factor. There is a need to balance the 
potential benefits of research into early diagnostic tests with the risks and ethical 
considerations for individuals with dementia and their families. 
Stigma 
This project has encouraged me to reflect on the issue of stigma in dementia. This 
stigma is rooted in misconceptions about incapacitation and dependency (Batsch & 
Mittelman, 2012). Stigma has been highlighted as a key contributing factor to delays 
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in the diagnosis of dementia (Vernooij-Dassen et al., 2005; Burgener & Berger, 
2008) and a reluctance to participate in research studies (Garand, Lingler, Connor, & 
Dew, 2009), with less than 4% of individuals with dementia participating in clinical 
research studies in the UK (Department of Health, 2012a). Furthermore, GP’s 
perceptions of dementia have been shown to map on to conceptualisations of stigma 
and hinder timely diagnosis (Gove, Downs, Vernooij-Dassen & Small, 2016). 
National and international policy publications on dementia tend to focus on the 
consequences of growing prevalence and report statistics in terms of care and cost 
‘burden’ The descriptions in these documents portray a sense of urgency and fear 
around dementia. The use of language in these policy documents reflects some of the 
dominant, stigmatizing narratives about dementia. Through my experience of 
working with older people, I have had conversations with clients about their fears 
about dementia and becoming a ‘burden’ on others. These reflections have 
highlighted for me the need to have externalising conversations to support older 
people and their families and carers in separating what is defined as a presenting 
problem from the person’s identity (Morgan, 2000). Carrying out this research has 
caused me to reflect on my own perceptions of dementia and to challenge my own 
susceptibility to these widely-held assumptions.  
Lived experience of dementia 
As I did not meet the participants whose data is reported on in this study, as a 
researcher I was far removed from their lived experiences. There is a dominance of 
studies investigating aetiology and pathology in dementia research and 
considerations of the lived experience of individuals with dementia are often 
neglected. An exception to this is the body of research investigating quality of life in 
dementia, however these studies are often informed by proxy caregiver reports and 
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the voices and opinions of individuals with dementia are less often heard. Predictors 
of quality of life in dementia include the quality of relationship with the carer as 
perceived by the person with dementia (Clare et al. 2014). O’Rourke, Duggleby, 
Fraser, & Jerke (2015) asked people living with dementia about their perspectives on 
what affects quality of life which included connection in relationships, agency in life, 
wellness and a sense of belonging. While early diagnosis of dementia is important 
for access to evidence-based treatments, listening to the perspectives of people 
experiencing dementia may be more beneficial in identifying where to intervene. It 
may be necessary to broaden the conceptualisation of dementia as a socially-
embedded phenomenon. Kitwood (1990) suggested that dementia is composed of 
interactions between the neuro- logical impairment and life history, health status, 
personality and malignant social psychology. This conceptualisation may serve to 
focus efforts on improving care and quality life for persons with dementia and their 
carers. 
Conclusion 
I was motivated to assess the utility of a spatial memory tool for the purposes of 
improving the early diagnosis of dementia. I was also keen to investigate tools which 
assist clinicians in detecting and treating anxiety in the dementia population. 
Analysing MRI data was a challenging undertaking as the main task of a DClinPsy 
research project. It required close working with an experienced collaborator and the 
learning of novel skills. The limitations of working with a pre-determined sample 
were further hindered by the technical challenges of the analysis. For me this project 
has highlighted the gap between research and clinical practice in the early diagnosis 
of dementia and has helped me to more closely consider the lived experience of 
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individuals with dementia and how this knowledge is essential in future 
developments of diagnostic assessments and treatment. 
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Appendix 1: Data permission letter 
 
Maura Scanlon 
Trainee Clinical Psychologist 
UCL Division of Psychology and Language Sciences 
1 - 19 Torrington Place 
London. WC1E 7HB 
 
19/04/2017 
 
Dr Joshua Stott 
Research department of clinical, educational and health Psychology 
University College London, 
London, UK, 
WC1E 6BT 
 
Dear Dr Stott, 
Running Title of Project: The clinical utility of the Four Mountains Test in the diagnosis of 
dementia: relationship to hippocampal atrophy. 
I am writing to request permission for the use of data from the cohort of participants recruited for your 
study: 
Stott, J., Scior, K., Mandy, W., & Charlesworth, G. (2017). Dementia Screening Accuracy is Robust 
to Premorbid IQ Variation: Evidence from the Addenbrooke’s Cognitive Examination-III and the Test 
of Premorbid Function. Journal of Alzheimer's Disease, (Preprint), 1-10. 
 
This data will be analysed and used as part of a thesis submission for a Doctorate in Clinical 
Psychology (DClinPsy) at University College London. 
Yours Sincerely, 
Maura Scanlon 
Trainee Clinical Psychologist 
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Dear Dr Stott 
 
Study title Exploring cognitive mediation ability in people with 
dementia: the factors that influence it and effects of 
difference in ability 
REC reference: 14/LO/0554 
Amendment number: Substantial Amendment 1 
Amendment date: 17 April 2015 
IRAS project ID: 147241 
 
The above amendment was reviewed on 19 June 2015 by the 
Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a 
favourable ethical opinion of the amendment on the basis described in 
the notice of amendment form and supporting documentation. 
 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Interview schedules or topic guides for participants [MBAT script]   
Notice of Substantial Amendment (non-CTIMP) [ including 
more routine clinical data, addition of mindfulness] 
Substantial 
Amendment 
1 
17 April 2015 
Other [Sections of original submission affected by proposed 
amendments] 
  
Participant information sheet (PIS) [Clinical PIS Stage 1 CB] 5 (clean) 10 April 2015 
Participant information sheet (PIS) [Clinical PIS Stage 1 CB] 4-5 (tracked) 17 June 2015 
Validated questionnaire [CAMS R questionnaire with instructions]   
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Membership of the Committee 
 
The members of the Committee who took part in the review are listed on 
the attached sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D 
office for the relevant NHS care organisation of this amendment and check 
whether it affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully with the 
Standard Operating Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES 
committee members’ training days – see details at http://www.hra.nhs.uk/hra-
training/ 
 
 
Yours sincerely 
 
Dr Koula Asimakopoulou Acting Alternate Vice Chair 
 
E-mail: nrescommittee.london-cityroadandhampstead@nhs.net 
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14/LO/0554: Please quote this number on all correspondence 
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